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Dr Luca Passamonti 
Tau pathology, microglia activation, and network dysfunction in Alzheimer’s disease 
Tau pathology and neuroinflammation are key etio-pathogenetic mediators 
of Alzheimer’s disease (AD). Network dysfunction has also been reported in 
AD and linked to cognitive impairment. However, it is unclear how tau 
pathology and neuroinflammation contribute to network dysfunction and 
cognitive deficit in AD.  
 
I study these issues by combining: 1) positron emission tomography 
imaging using the [18F-AV]-1451 tracer (measuring in vivo tau pathology) 
or [11C]PK11195 ligand (indexing in vivo neuroinflammation), with 2) 
connectivity measures of resting-state functional magnetic resonance 
imaging.  
 
I found increased [18F-AV]-1451 binding (reflecting tau pathology) in AD 
patients, relative to controls, in the medial/lateral temporal and parietal 
cortices. In terms of functional connectivity, more strongly connected brain 
regions accrued more tau pathology. Increasing tau burden was also linked 
to progressive weakening of the connectivity across the same regions.  
 
I also found increased [11C]PK11195 binding (reflecting neuroinflammation) 
in the medial/lateral temporal and parietal cortices in AD patients, relative 
to controls. [11C]PK11195 binding in the cuneus/precuneus correlated with 
episodic memory deficits in AD patients. This pattern of neuroinflammation 
was linked to large-scale network’ dysfunction and cognitive deficit. AD 
patients with enhanced neuroinflammation showed more abnormal 
connectivity across the whole-brain. The expression of a stronger 
association between altered functional connectivity and high levels of 




My studies have wide-ranging implications that include:  
 
1) the validation of animal models of tau propagation in living patients with 
AD;  
 
2) improvements in our understanding of the relationship between in vivo 
tau pathology and brain functioning;  
 
3) evidence for a primary role of neuroinflammation in mediating network 
dysfunction in AD;  
 
4) support to the notion that immune-therapeutic strategies targeting tau 




The patient and control data used throughout this thesis have been 
collected by myself and a team of researchers and clinicians at the 
Department of Clinical Neurosciences working in the context of the NIMROD 
study.  
 
Chapter 2 summarises the relevant parts of the protocol of the NIMROD 
study. The NIMROD study is a collaboration led by Professors James B. 
Rowe and John O’Brien, with research assistant support from Dr Richard 
Bevan-Jones, Patricia Vazquez Rodriguez, and Mr Robert Arnold. I 
undertook part of the clinical investigations and assessments, especially 
those related to the AD and control group. This chapter has been published 
at BMJ Open (Bevan-Jones et al., 2017). 
 
Chapter 3 includes tau (‘AV’) PET data obtained under the NIMROD 
research study collected by me, Mr Robert Arnold, Patricia Vazquez 
Rodriguez, and Dr Richard Bevan-Jones. The analysis, interpretation, and 
writing of this Chapter represent my own work which has been published in 
Passamonti et al., Brain, 2017 in collaboration with Patricia Vazquez 
Rodriguez (co-first author). 
 
Chapter 4 includes the combination of the AV PET data described in 
Chapter 3 and the rsfMRI data obtained under the NIMROD research study 
collected by me, Mr Robert Arnold, Patricia Vazquez Rodriguez, and Dr 
Richard Bevan-Jones. My contribution to this Chapter (published in Cope et 
al., Brain 2018) includes the conception and design of the study, acquisition 
of data, and drafting of the manuscript. 
 
Chapter 5 includes neuroinflammatory (‘PK’) PET data obtained under the 
NIMROD research study collected by me, Mr Robert Arnold, Patricia Vazquez 
Rodriguez, and Dr Richard Bevan-Jones. The analysis, interpretation, and 
writing represent my own work which has been published in Passamonti et 
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al., Neurology, 2018 in collaboration with Patricia Vazquez Rodriguez (co-
first author). 
 
Chapter 6 includes the combination of the PK PET data described in Chapter 
5 and the rsfMRI data obtained under the NIMROD research study collected 
by me, Mr Robert Arnold, Patricia Vazquez Rodriguez, and Dr Richard 
Bevan-Jones. The analysis, interpretation, and writing of this Chapter 
represent my own work which has been published in Passamonti et al., J 
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Chapter 1 | Introduction 
1.1. Overview 
My thesis examines how in vivo tau pathology and neuroinflammation relate 
to network dysfunction and cognitive deficit in in Alzheimer’s disease (AD), 
the most common neurodegenerative form of dementia. AD has a broad 
clinical phenotypic spectrum that include typical and atypical forms. 
However, both types of AD share key molecular pathologies including 
abnormal accumulation of tau aggregates, amyloid pathology, and chronic 
neuroinflammation.  
 
My work focuses on the typical (i.e., amnestic) form of AD and I investigate 
the effects of tau pathology and neuroinflammation on network dysfunction 
and cognitive impairment in this form of AD. I combine positron emission 
tomography assessing in vivo tau pathology and neuroinflammation with 
resting-state functional imaging. This multi-modal approach offers better 
insights into the pathophysiology of a common neurodegenerative disorder 
such as AD.  
 
Together, my studies highlight the need for better methods to evaluate the 
pathology of AD in vivo, and to reveal the critical links between pathological 
changes, functional alterations, and individual differences in cognitive 
performance.  The combination of different neuroimaging techniques also 
raises important methodological issues which I examine in my thesis. 
 
In this Chapter, I first set out the background of the clinical, genetic, and 
molecular aspects of AD. Second, I present the neuroimaging tools that 
enable the in vivo examination of tau pathology, neuroinflammation, and 
brain function in AD. Finally, I conclude this chapter with a summary of the 




1.2. Clinical description of Alzheimer’s disease (AD) 
1.2.1. History of AD and mild cognitive impairment (MCI)  
The Alzheimer’s disease (AD) was initially described by Dr Alois Alzheimer, 
who was the first to report the presence of severe pathological changes in 
the cerebral cortex of a 50-year-old lady who had died of a relatively rapid 
mental illness of unknown causes (Hippius & Neundörfer 2003). In his 
original description, Dr Alzheimer described a woman who suffered from 
memory deficits, language abnormalities, sleep problems, and mental 
symptoms that included paranoiac thoughts and bizarre behaviour. Since 
Dr Alzheimer’s original description, and for several decades after, AD was 
regarded as a rare and young-onset form of dementia while the more 
common types of late-onset dementia was typically considered as “senile” 
(or age-related) dementia. It was only in the late 1970s’ and early 1980s’ 
that AD and its characteristic pathological changes were commonly 
recognized as the main cause of late-onset forms of dementia.  
 
Historically, the concept of ‘Mild Cognitive Impairment’ (MCI) was 
introduced later than the initial description of AD. The notion of MCI was 
mainly developed to include the clinically less disabling forms of cognitive 
deficits that belong to the clinical spectrum of AD (Flicker et al. 1991). MCI 
was defined as a less severe type of cognitive impairment than the one 
present in AD. For example, MCI relates to problems in single cognitive 
domains (e.g., episodic memory) rather than on multiple cognitive aspects 
as in AD. The severity of the cognitive impairment in terms of patient 
lifestyle and everyday activities is another important aspect that 
distinguishes MCI from AD. 
 
More recently, the definition of MCI has incorporated the presence of 
biomarkers of AD pathology. Specifically, biomarker evidence of tau and 
amyloid pathology in patients with MCI indicates that these MCI patients 
are more likely to progress and develop AD dementia relative to those MCI 
patients who are negative for these biomarkers (stable MCI) (Loewenstein 
et al. 2009). Some patients with stable forms of MCI can even revert to 
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normal cognition especially when the diagnosis of MCI is based on the 
results of a single, rather than multiple, neuropsychological tests 
(Loewenstein et al. 2009). These findings emphasize the importance of a 
deep neuropsychological phenotyping in patients with MCI, which should 
include assessment at least in two cognitive domains  (Loewenstein et al. 
2009). This is particularly relevant for clinical trials targeting AD pathology 
that aim at recruiting patients at early stages of AD or with MCI and high 
risk to develop AD (Loewenstein et al. 2009) 
 
1.2.2. Diagnostic criteria of AD and MCI 
AD is typically defined at the clinical level, although there have been 
significant changes in the clinical criteria used in the past. The most 
commonly used clinical criteria for the diagnosis of AD are those developed 
by the Alzheimer's Disease and Related Disorders Association (ADRDA) 
(McKhann et al. 2011a). These criteria classify AD in: 1) “probable AD”, in 
which frank and severe cognitive impairments that include memory deficits 
and at least deficits in one other cognitive domain are recognized, or 2) 
“definite AD” which includes those cases that have received confirmation of 
AD diagnosis at the pathological level (McKhann et al. 2011a).   
 
Previously, the International Working Group (IWG) led by Dubois and 
collaborators (Dubois et al. 2007b) had conceptualized the AD spectrum in 
three stages that depended on the combination of clinical symptoms and 
biomarker assessment. Three stages were recognized in the IWG criteria: 
1) the clinically asymptomatic but biomarker-positive forms of AD; 2) the 
MCI and biomarker-positive forms of AD; 3) the frank forms of AD 
dementia.  
 
The key elements of the IWG criteria are: 
 
i. It is possible to diagnosize AD not only post mortem but also in vivo 
via the use of objective and reliable biomarkers. 
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ii. The positivity of biomarkers enhances the confidence to detect AD-
pathology before pathological confirmation and in early cases of MCI 
without frank forms of dementia.  
 
iii. AD pathology can be assessed even in patients with no cognitive or 
memory problems. 
 
iv. The integration of fluid biomarkers (e.g., Aβ, tau quantification in the 
CSF) and neuroimaging measures from different modalities (e.g., PET, MRI) 
has a role in anticipating the diagnosis of AD in pre-symptomatic cases and 
early forms of dementia.  
 
After the IWG, the National Institute on Aging (NIA) and Alzheimer's 
Association (AA) have developed other criteria to define AD (Jack et al. 
2011). Similar to the IWG criteria, the NIA/AA criteria include the use of 
biomarkers to detect early AD-pathology.  
 
The NIA/AA criteria are summarized in Table 1. 
 
Stages Features 
Preclinical AD Before symptoms appear but initial changes are 
present in the default mode network (Nobili & 
Morbelli 2010). 
MCI Noticeable symptoms begin, and dementia is 
anticipated in three to four years (Albert et al. 
2011a). 
Dementia due to AD Daily function is impaired (Thies et al. 2013). 
 
Table 1: The NIA and AA criteria (2011). 




Although different, the IWG and NIA/AA share many elements in their 
recognition of the early emergence of AD-related pathological features 
before the onset of frank dementia. The three stages of AD conceptualized 
in both criteria acknowledge the pathological and phenotypic continuum 
that exists in AD.  
 
However, the IWG criteria describe AD as a unique clinico-pathological 
entity that embraces all the clinical stages of AD while the NIA/AA criteria 
apply different diagnostic criteria to each of the three phases of AD. This 
means that the NIA/AA MCI criteria do not explicitly recognize a continuity 
with the AD clinical spectrum of disorders and do not incorporate the use of 
biomarkers in the diagnosis of MCI, although the biomarkers are considered 
supportive to the AD diagnosis due to the highly variable nature of the MCI 
clinical phenotypes (i.e., stable vs. progressive-MCI) (Jicha et al. 2006; 
Ganguli et al. 2011). 
 
1.3. Genetics of AD  
Although the majority of cases with AD (>90%) are sporadic and non-
inheritable, the studies of the genetic risk factors have provided invaluable 
information regarding the etiology of AD (Prince & Jackson 2009), (van 
Duijn et al. 1994; Campion et al. 1999; Jarmolowicz et al. 2015), (Campion 
et al. 1999; Jarmolowicz et al. 2015). For example, genome-wide-
association studies (GWAS) have revealed the critical importance of the 
apo-lipoprotein E (ApoE-ε4 haplotype) as a key risk factor for AD (Deelen 
et al. 2011; Sebastiani et al. 2012).  
 
More recently, a key etiological role for immune-related molecular pathways 
and neuroinflammation has been recognized in AD. For example, GWAS 
have identified genetic variants in the Triggering receptor expressed on 
myeloid cells 2 (TREM2), an immune-related gene expressed in microglia, 
as another important genetic risk factors for AD, is similar to the ApoE-ε4 
haplotype (Jonsson et al. 2013c; Neumann & Daly 2013). In addition, 
variations in other genotypes including the SORL1 (sortilin-related 
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receptor) gene have been linked to risk to develop AD (Rogaeva et al. 2007; 
Guerreiro et al. 2013b; Jonsson et al. 2013a).  
 
Overall, these studies have led to the identification of the genetic risk profile 
in AD and represent a scientific breakthrough, although they have not been 
able to explain the pathophysiological mechanisms that lead to the 
characteristic clinical symptoms in AD.  
 
None of the patients included in my studies had familial forms of AD or were 
known to be positive for mutations in MAPT, APP, PSEN1, PSEN2, TREM2 or 
ApoE-ε4 genes. In other words, the patients described in my thesis were 
not included neither excluded on the basis of genetic data. 
 
1.4. Molecular pathologies in AD  
1.4.1. Tau pathology  
The normal Tau protein is typically expressed in neuronal cells and is 
essential for the correct function of their microtubules, a set of macro-
molecular elements that form the neuronal cytoskeleton (Weingarten et al. 
1975). Chemical phosphorylation of the Tau protein is another important 
determinant of Tau physiological function, although the excessive 
phosphorylation of the neuronal Tau protein has also been consistently 
associated with AD-pathology and with the abnormal aggregation and 
accumulation of different Tau isoforms. Tau aggregation is a pathological 
‘hallmark’ of AD and it is expressed by the  presence of intra-neuronal 
filamentous tangles (Buée et al. 2000; Martin et al. 2011).  
 
Several lines of research have provided robust evidence that the generation 
and propagation of ‘toxic’ Tau proteins represent a fundamental etio-
pathogenetic mechanism not only in AD but also in other, non-AD, 
tauopathies or dementias (Spillantini et al. 1998; D’Souza & Schellenberg 
2005; Goedert & Jakes 2005; Kaat et al. 2009; Martin et al. 2011). It is 
therefore of primary importance and interest to study tau pathology in early 
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cases of AD, in which pathological spread of tau can be potentially halted 
or slowed.  
 
The microtubule-associated-protein (MAPT) gene, which is located on the 
chromosome 17q21 (Neve et al. 1986), codes for the human Tau protein. 
The MAPT gene can be transcribed into six different isoforms, from 
alternative splicing that include or not the gene exons 2, 3, and 10 (Avila 
et al. 2004; Andreadis 2005). The tau isoforms that contain the exon 10 
result in a Tau protein that include four microtubule-binding repeats (tau 
4R isoforms). In contrast, the tau isoforms that do not include the exon 10 
result in Tau protein that contains three microtubule-binding repeats (tau 
3R isoforms). The abnormal tau deposits in AD (i.e., in the neurofibrillary 
tangles) are typically formed by both the four (4R) and three (3R) Tau 
isoforms and by paired helical filaments of a diameter between 10-20 nm 
(Sisodia et al. 1990; Liu et al. 2001).  
 
Another important aspect of tau pathology in AD regards the mechanisms 
by which the abnormal Tau proteins diffuse to various brain regions as the 
disease progresses. Animal research has provided converging evidence that 
local tau pathology can have ‘infectious’ properties especially in terms of its 
diffusion and spread of the disease from one area of the brain to another 
one. However, it has remained unclear whether the same mechanisms that 
regulate this pathological Tau ‘spread’ can be detected in humans. In 
Chapter 4, we combine network analyses, as assessed via resting-state 
functional imaging, with in vivo molecular imaging of tau pathology to study 
this critical pathophysiological mechanism in AD in humans. 
 
From a pathological point of view, it is also clear that the progression of tau 
pathology in AD typically follows a consistent pattern of diffusion which has 
been used to define six ‘Braak’ stages of AD pathology (Braak & Braak 
1991a). At stage I and II, Tau pathology is mainly detected in the trans-
entorhinal and entorhinal cortex. At stage III and IV, different parts of the 
hippocampus (e.g., Cornus of Ammones 1, CA1) become affected by Tau 
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pathology (Figure 1, Figure 2, Figure 3). Finally, at stage V and VI, 
abundant and diffuse Tau pathology is observed in cortical areas including 
the temporal, parietal, and other posterior cortical regions (Figure 4). Each 
pathological ‘Braak’ stage of AD-related Tau pathology corresponds to a 
specific clinical stage. Patients in pathological stages V and VI typically meet 
the clinical criteria for AD diagnosis and are severely demented at the time 
of death. The cognitive impairment in patients with lower pathological Braak 
stages can range from asymptomatic to MCI (Braak & Braak 1991b; Price 
et al. 1991).  
 
Abnormal Tau accumulation and diffusion have also been considered in the 
context of the other pathological hallmark of AD, i.e, the accumulation of 
amyloid-β, and to a newly recognized but critical etio-pathogenetic 
mediator of AD (i.e., neuroinflammation), which I will discuss in the next 
sections (Desikan et al. 2012; Jack & Holtzman 2013).  Nevertheless, past 
pre-clinical research has clearly demonstrated that tau pathology in itself 
has deleterious effects on cell survival and synaptic function (Gómez-Isla et 
al. 1997; Beharry et al. 2014; Spires-Jones & Hyman 2014), and that Tau 
pathology, rather than amyloid-β pathology, is more strongly linked to 
cognitive impairments in AD and with the different phenotypes of the AD 
clinical spectrum (Arriagada et al. 1992a; Nelson et al. 2012; Rolstad et al. 
2013).  
 
For example, the extent and distribution of tau pathology in vivo correlates 
with distinct clinical variants of AD, including, for example, the posterior 
cortical atrophy (PCA) and logopenic variant of primary progressive aphasia 
(lvPPA). In these AD-related clinical syndromes, tau molecular imaging with 
the PET [18F]AV1451 radioligand has been found to be associated to higher 
levels of hypometabolism and cognitive deficits than amyloid-β deposition, 




Figure 1: Midsagittal view of an Alzheimer’s disease (AD) brain  
The medial aspect of the left hemisphere shows moderate to severe atrophy of the 
neocortex and of the medial temporal lobe including the hippocampus. The weight of this 
brain was 1,180g (normal brain weight range: 1,300-1,400). Image kindly provided by Dr 




Figure 2: Microscopic view  of the hippocampus in AD. 
Left. Staining for different hippocampal sub-fields. CA; Cornus of Ammones, DG, Dentate 
Gyrus. Right Staining for tau pathology (in brown). Tau pathology is evident in different 
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hippocampal sub-fields especially CA1. Image kindly provided by Dr Kieren Allinson from 
the Cambridge Brain Bank. 
 
Figure 3: Microscopic view of the hippocampus (CA1) in AD. 
Left. Staining for hippocampal neurons in the CA1 sub-field. Right, Staining for tau 
pathology (in brown). Image kindly provided by Dr Kieren Allinson from the Cambridge 
Brain Bank.   
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Figure 4: Microscopic view of the parietal cortex in AD (tau pathology). 
Staining for tau pathology (in brown). Image kindly provided by Dr Kieren Allinson from 
the Cambridge Brain Bank. 
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1.4.2. Amyloid pathology  
The role of pathological accumulation of β-amyloid in AD patients is a well-
established etio-pathogenetic aspect of AD (Figure 5). This is known as the 
“amyloid cascade hypothesis”. This hypothesis has implicated the formation 
of β-amyloid fibrils (Aβ) as the main event that determines the tau hyper-
phosphorylation and the consequent development of neurofibrillary tangles 
(NFT), cell dysfunction, neuronal loss, and ultimately dementia (Beyreuther 
& Masters 1991; Hardy & Allsop 1991). However, this hypothesis remains 
controversial especially after the recent lack of success of some disease-
modifying clinical trials selectively targeting amyloid pathology in AD.   
 
Other studies have also consistently reported that it is the tau pathology, 
and not the amyloid burden in itself, that correlates with cognitive 
impairment, disease severity, and clinical phenotypic spectrum in AD 
(Arriagada et al. 1992b; Buchhave et al. 2012). Nevertheless, the 
biomarkers assessing amyloid pathology in vivo remain a fundamental 
diagnostic tool to discriminate the MCI patients who are likely to develop 
AD pathology over 2-5 years from those who do not develop AD (Reisberg 
et al. 1982; Flicker et al. 1993; Gauthier et al. 2006; Wisse et al. 2015). 
 
My thesis does not examine the β-amyloid hypothesis in AD. However, I 
employ an amyloid imaging biomarker (PiB PET) to identify a group of 
patients in which their MCI is driven by AD-related amyloid pathology.  I 
also include patients with clinically probable AD as defined by the ADRDA 
criteria. The use of amyloid biomarkers in this group of clinically probable 
AD was not thought to be necessary, especially considering: 1) the high 
sensitivity (up to 87%) of the ADRDA criteria in predicting post mortem AD 
pathology in clinically probable cases; 2) the high costs of PET scanning. 
 
To summarize, only the MCI patients who were amyloid positive (MCI+) 
were included in my analyses. To assess amyloid pathology in vivo, we 
employed PiB PET imaging as this ligand has the longest history as a 
amyloid biomarker for clinical use (Mathis et al. 2002). Nevertheless, I 
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acknowledge that other, and potentially more accessible (as they include 
[18F] rather than [11C]), compounds are nowadays available (e.g., 
flutemetamol, florbetaben, florbetapir) (Villemagne et al. 2011; Thurfjell et 
al. 2012; Ong et al. 2013; Martinez et al. 2017).  
 
 
Figure 5: Microscopic view of the parietal cortex in AD (amyloid pathology).  
Staining for amyloid pathology (in brown). Image kindly provided by Dr Kieren Allinson 
from the Cambridge Brain Bank.  
  
 32 
1.4.3. Microglia activation and neuroinflammation  
Microglia activation and neuroinflammation are another key molecular 
contributor to the etio-pathogenesis of AD. Animal and human studies have 
provided robust evidence that microglia, the brain’s principal innate immune 
system, show increased activation in AD and other neurodegenerative 
disorders (Fernandez-Botran et al. 2011a; Edison et al. 2013a; 
Schuitemaker et al. 2013a; Fan et al. 2015a; Stefaniak & O’Brien 2016a) 
(Figure 6). For instance, there is evidence that the microglia-mediated 
release of cytokines such as interleukin-1ß and TNF-ß can accelerate 
neurodegeneration and synaptic loss in AD (Fernandez-Botran et al. 
2011a). On the other hand, activated microglia has also been shown to 
promote phagocytosis and clearance of amyloid plaques (Wisniewski et al. 
1991; Frackowiak et al. 1992).  
 
In addition, genome wide associations studies (GWAS) in different 
neurodegenerative disorders including AD have revealed that variations in 
genes that contribute to immune signalling are important risk factors in AD 
(Villegas-Llerena et al. 2016). There is also epidemiological evidence 
showing that patients using non-steroidal anti-inflammatory drugs have a 
reduced risk to develop dementia and AD  (Breitner & Zandi 2001; in t’ Veld 
et al. 2001). 
 
This raises the possibility of using immuno-therapeutic strategies for 
preventing the development of AD or even as disease modifying treatments. 
However, key issues need to be addressed before such strategies can be 
employed, including the confirmation of clinico-pathological correlations of 
neuroinflammation and the establishment of the potential utility of 
biomarkers for measuring neuroinflammation in vivo. Despite the 
importance of neuroinflammation, there is still insufficient information 
regarding the extent and regional distribution of microglial activation in AD, 
and its association with clinical markers of disease severity. I tackle these 
issues in my thesis and I also study the role of neuroinflammation and 
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microglia activation in mediating network dysfunction and variability in 
cognitive deficit in AD. 
 




Figure 6: Microscopic view (microglia activation) in AD.  
This figure aligns the HLA-DR staining (in brown, reflecting activated microglia) in one key 
region of interest (i.e., hippocampus) in an Alzheimer’s disease (AD) case (left), and a 
control of similar age (right). Activated microglia was mainly identified in the hippocampus 
of the AD case. In contrast, the control case did not show activated microglia staining in 




1.5. Interim summary 
The characterization of AD at the clinical, genetic, and pathological level is 
still evolving, in part due to rapid developments in the biomarker research 
field. The recent introduction of the concept of asymptomatic AD with 
biomarker evidence emphasizes the need to develop better models that 
describe, in neurobiologically realistic terms, the complexity of AD 
pathophysiology.In other words, it is necessary to characterize with 
quantitative and objective measures how the molecular pathologies of AD 
lead to brain dysfunction and cognitive impairment.  
 
This is the first critical step before developing biomarkers that can de-risk 
and empower future clinical trials in AD via improved outcome measures 
and mechanistically-informed stratification procedures.  
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1.6. Positron Emission Tomography (PET) in AD 
Positron emission tomography (PET) is a diagnostic imaging modality that 
uses isotope-labelled molecular ligands to probe specific biomolecules of 
interest with both high specificity and affinity. When I started my thesis, 
there were only a few studies on tau pathology and neuroinflammation 
using PET imaging biomarkers in vivo in AD but nowadays the number of 
PET studies using tau imaging and neuroinflammation has greatly 
expanded.  
 
In Chapter 3 and 5, I discuss in more detail the most recent PET studies 
assessing tau pathology and microglia activation. Nevertheless, to fulfil the 
potential of these PET ligands as biomarkers, we still need to answer several 
important questions, including: 1) the ability of these ligands to localize and 
quantify the underlying pathological process, with high specificity and 
sensitivity, 2) the ability of these tracers to relate to clinical features 
including severity of cognitive impairment, directly or via the mediation of 
network function, and 3) the ability of these PET markers to track disease 
progression longitudinally. 
 
My thesis focuses on questions 1) and 2) and present data from PET tracers 
assessing in vivo tau pathology and neuroinflammation. In the following 
sections, I briefly introduce part of the literature on PET biomarkers 
assessing tau and amyloid pathology as well as neuroinflammation in AD.  
 
1.6.1. PET to assess tau pathology in AD 
 [18F]AV1451 (formerly called [18F]T807) was one of the first PET 
radioligand introduced to study the tau pathology in AD and MCI in vivo. 
Chien et al. were the first to show that in vivo cortical [18F]AV1451 binding 
recapitulates the well-known distribution of tau pathology in AD, in which 
higher [18F]AV1451 uptake was related to increasing disease severity 
(Chien et al. 2014). More recently, Schöll’s et al. have reported that patients 
with early-onset AD already display increased [18F]-AV-1451 uptake in 
several cortical regions, while enhanced [18F]-AV-1451 binding in medial 
 35 
temporal lobe regions is only seen in late-onset AD (Schöll et al. 2017). 
Since these reports, there have been several other studies which have 
consistently reported increased [18F]AV-1451 binding in MCI amyloid 
positive patients and in people with clinically probable AD including our 
studies reported in Chapter 3 and 4.  
 
When the data collection for my thesis started, the [18F]AV1451 PET tracer 
was one of the few available compounds. I will discuss this ligand in detail 
in Chapter 3 and 4. Since then, other tracer targeting tau pathology in AD 
have been developed, including [18F]THK523, [18F]THK5105, [18F]THK5117, 
and [11C]PBB3 which I briefly review here. 
 
Studies of [18F]THK523 in animal models indicated that this tracer 
selectively binds to tau pathology in AD brains. In addition, 
autoradiographic and histo-fluorescent data of THK523 hippocampal 
sections from human brain tissue have shown high affinity and selectivity 
of this ligand for tau pathology (Fodero-Tavoletti et al. 2011). However, the 
preclinical data also reported that the pharmacokinetics and binding 
characteristics of [18F]THK523 do not meet the threshold required for PET 
tracers with high sensitivity and specificity.  
 
More specifically, it was concluded that the [18F]THK523 uptake in AD 
patients was too similar to that observed in healthy controls (V.L. et al. 
2012). Successively, there have been further optimization of the 
[18F]THK523, [18F]THK5105, and [18F]THK5117 tracers (Okamura et al. 
2013a), but in all of these additional developments of the [18F]THK tracers 
‘off-target’ binding was noted especially to the monoamine oxidase-B 
enzyme (Hirvonen et al. 2009; Gulyás et al. 2011; Ng et al. 2017). 
 
[11C]PBB3 reversibly binds to neurofibrillary AD-related tau tangles with 
high affinity and selectivity (Maruyama et al. 2013b; Hashimoto et al. 
2014). Moreover, accumulation of [11C]PBB3 has been seen in the medial 
and lateral temporal cortices, and the frontal cortex—consistent with the 
 36 
Braak staging of AD (Maruyama et al. 2013b). [11C]PBB3 has also been 
recently tested in non-AD tauopathies including progressive supranuclear 
palsy (PSP) and corticobasal degeneration (CBD) (Sahara et al. 2017). In 
these tauopathies. a degree of specificity of this tracer was reported, at 
least when the [11C]PBB3 binding in PSP and CBD was compared to that of 
healthy controls (Shimada et al. 2016). However, additional studies need 
to assess the specificity of this tracer in the differential diagnosis between 
AD and non-AD tauopathies. 
 
1.6.2. PET to assess amyloid pathology 
The 11CPiB PET tracer has revolutionized the in vivo molecular imaging of 
AD and has allowed to track for the first time a critical pathological aspect 
of AD (i.e., abnormal amyloid deposition)(Klunk et al. 2004; Jack et al. 
2008). As expected from post mortem research, patients with MCI and PiB 
evidence of amyloid pathology are more likely to convert to AD rather than 
PiB negative MCI patients (Forsberg et al. 2008)(Engler et al. 2006). The 
ability of the 11CPiB PET tracer to identify AD pathology is elevated and 
reach around 96% of accuracy (Johnson et al. 2012).  
 
Longitudinal studies using 11CPiB PET have also revealed that people at high 
risk of developing AD due to genetic mutations show increased amyloid 
burden when assessed with 11CPiB PET(Reiman et al. 2009)(Reiman et al. 
2009). However, the 11CPiB PET shows limited ability to characterize the 
phenotypic complexity of AD (O’Sullivan & Vann 2016). In other words, 
there is poor correlation between the 11CPiB PET signal and the clinical 
spectrum of AD, in terms of localization of the phenotypic syndromes and 
in terms of regional deficits in glucose metabolism (O’Sullivan & Vann 
2016). The amyloid burden that is quantified by the 11CPiB PET tracer can 
be found in several brain regions, even those which might not have 
immediate relevance at the symptomatic level (O’Sullivan & Vann 2016). 
Consistently, the correlation between the amyloid burden detected via 
11CPiB PET tracer and glucose hypo-metabolism, brain atrophy, and disease 
progression is limited (O’Sullivan & Vann 2016). 
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1.6.3. PET to assess microglia activation 
In vivo microglia activation in the brain can be assessed using PET imaging 
in conjunction with radio-ligands like [11C]PK11195. The [11C]PK11195 
tracer binds to the mitochondrial translocator protein (TSPO) that is present 
in the activated microglia. Compounds such as [11C]PK11195 are widely 
used biomarkers of microglia activation, although it is important to bear in 
mind that microglial activation represents only a part of the complex 
cascade of events that lead to neuroinflammation in AD and other disorders.  
 
Amongst the first-generation TSPO tracer, [11C]PK11195 has been also 
widely used to study microglial activation in several other neurologic 
disorders in which neuroinflammation play a central role. These include for 
example acute neurological conditions such as stroke (Price et al. 2006), 
multiple sclerosis (Banati et al. 2000), and other chronic neurodegenerative 
disorders like Parkinson’s disease (Gerhard et al. 2006a), corticobasal 
degeneration (Gerhard et al. 2004), and Huntington’s disease (Pavese et 
al. 2006). There is also a study in healthy elderly people showing that 
[11C]PK11195 PET can demonstrate increased TSPO density in ‘normal’ 
brain aging (Kumar et al. 2012).  
 
In AD, microglial activation detected through [11C]PK11195 binding has 
been reported in the entorhinal, temporo-parietal, and other cortical 
regions that are typically affected by AD-related neurodegeneration in early 
stages. This suggests that neuroinflammation could be considered as an 
early factor in the pathogenesis of AD rather than merely reflecting a 
consequence of brain atrophy (Cagnin et al. 2001a; Okello et al. 2009a). In 
addition, post mortem studies have consistently shown increased microglia 
activation and cytokine release in the frontal cortex, parietal and occipital 
cortices in patients with AD pathology (Fernández-Botrán et al. 2011). 
Enhanced [11C]PK11195 binding in several cortical and subcortical regions 
has also been found in patients with MCI (Cagnin et al. 2006).  
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1.7. Magnetic resonance imaging (MRI) in AD 
Magnetic resonance imaging (MRI) is another standard imaging technique 
in both research and clinical assessment of patients with AD. For the 
purposes of my thesis, I describe the two main MRI modalities that enables: 
(a) the visualization of the disease-specific patterns of neurodegeneration 
and atrophy in AD (structural MRI, section 1.7.1), and (b) the study of the 
function of single brain regions and large-scale networks (functional MRI, 
section 1.7.2.). Together, as well as in conjunction with the PET imaging 
modalities described in section 1.6, these MRI indices offer important 
information that not only facilitates clinical diagnosis of AD, but also provide 
critical insights into its underlying pathophysiology (Iwata 2005; Berg et al. 
2011).  
 
1.7.1. Structural magnetic resonance imaging (MRI) in AD 
This is one of the most commonly employed MRI modalities to assess the 
early and late neuroanatomical changes associated with MCI and AD and 
for predicting, via the use of sophisticated machine-learning algorithms, the 
disease course over time. In my thesis, structural MRI is only used in the 
context of PET and functional imaging analyses, although structural MRI 
data on the same AD patients described here have also been published 
separately (Mak et al. 2018). More specifically, in Mak et al. 2018, we have 
reported that cortical thinning in temporal cortices was related to tau 
pathology as assessed via the PET biomarker described in section 1.6.  
 
Other studies have also found that structural MRI markers including 
hippocampal atrophy and enlarged ventricles differentiate patients with AD 
from MCI patients and from age-matched healthy controls (Nestor et al. 
2008; Chou et al. 2009; Risacher et al. 2009, 2010) . Structural MRI can 
also be employed to predict the conversion from MCI to probable AD in 1 
year (Calvini et al. 2009; Misra et al. 2009) or 3 years (Spasov et al. 2019).  
 
In summary, several studies using structural MRI have converged to show 
that the rate of annual change in the whole-brain volume, hippocampal 
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atrophy, and ventricular enlargement are reliable predictors of AD 
pathology and its clinical progression (McEvoy et al. 2009; Morra et al. 
2009; Evans et al. 2010; Ho et al. 2010).  
 
1.7.2. Functional magnetic resonance imaging (MRI) in AD 
Although the effect of neurodegeneration on the patterns of brain atrophy 
detected with structural MRI have provided important and useful 
information for the diagnosis and prognosis of AD, the effects of 
neurodegeneration on network connectivity remain elusive.  
 
A better understanding of brain dysfunction in AD can have a more direct 
role in predicting response to both symptomatic and disease-modifying 
pharmacological therapies, as it is likely that the brain function is closer to 
the symptomatic level than the brain structure (Seeley et al. 2009; Pievani 
et al. 2011; Warren et al. 2012).  
 
Recently, most of the functional imaging studies that have investigated the 
network function in AD have employed task-free or ‘resting state’ 
paradigms. This is because rsfMRI has several advantages in clinical 
settings, relative to classic task-based fMRI. These advantages include:  
 
1) the minimization of cognitive training demands, which is critical in 
patients with AD;  
 
2) the lack of confounding effects linked to practice effects across different 
fMRI sessions;  
 
3) the possibility to examine ‘all at once’ (i.e., within the context of a single 
experimental session), several, although distinct, brain networks that would 
have otherwise required the use of many task-based fMRI sessions,  
 
4) the possibility to derive, from rsfMRI data, reliable measures of brain 
connectivity that can be used in network approaches. 
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All in all, I exploited these methodological advantages of rsfMRI to develop 
more realistic models of the brain functioning in AD, in relation to key 
pathological aspects such as tau pathology and neuroinflammation. 
 
Regarding the biological nature of the rsfMRI signal, this is thought to derive 
from the electro-physiological coherence among spontaneous neuronal 
oscillators, which may reflect the functional anatomy of distinct brain 
networks (Corbetta 2012). Critically, most of these ‘resting-state’ circuits 
also respond and create dynamic patterns of connectivity in response to 
specific task demands or during strictly manipulated experimental 
conditions.  
 
This supports the validity and reliability of using rsfMRI measures for 
studying cognition in healthy people and in patients with neurological 
disorders including AD (Kitzbichler et al. 2011). There is indeed consistent 
evidence that rsfMRI connectivity patterns are significantly altered in AD 
(Badhwar et al. 2017), although only few studies (including ours) have 
assessed how these abnormal patterns of network function relate to 
different molecular pathologies in AD (Cope et al. 2018; Yokoi et al. 2018; 
Passamonti et al. 2019).  
 




1.8. Multi-modal neuroimaging in AD  
A central aspect of the work described in my thesis regards the integration 
of different neuroimaging modalities. This raises a series of conceptual and 
methodological issues which I tackle in detail in Chapter 4 and 6. Briefly, 
one of the most important methodological issue is the necessity to integrate 
a large volume of different sources of information that are provided by 
distinct neuroimaging modalities. Hence, there is a need to reduce the 
complexity of the dataset and the necessity to minimize the number of 
statistical comparisons, especially when small sized populations are 
employed.  
 
More broadly, it is also important to acknowledge that different definitions 
of multi-modal neuroimaging exist (Uludağ & Roebroeck 2014). In this 
thesis, I use the term multi-modal neuroimaging to describe determinate 
analytical procedures that I have used to combine two or more 
neuroimaging datasets that have been acquired with different imaging 
modalities (i.e., fMRI and PET) in the same groups of participants.  
 
This neuroimaging data integration has the main advantage of improving 
our knowledge of the (dys)function of large-scale brain networks in AD by 
exploiting the physical (i.e., MRI-sensitive) and physiological (i.e., related 
to AD biology) sensitivities provided by each neuroimaging modality in 
isolation.  
 
This definition of multi-modal imaging is thus different from other 
definitions that for example refer to the fusion of imaging data obtained 
with the same physical instrument (e.g. combining perfusion- and diffusion-
weighted MRI in stroke imaging) (Uludağ & Roebroeck 2014).  
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1.9. Objectives of my thesis 
The main aim of my PhD was to improve our knowledge of how tau 
pathology and neuroinflammation mediate brain dysfunction and cognitive 
deficit in AD. To achieve this end, I structured my work in five distinct, 
although related, objectives.  
 
The first objective was to successfully recruit and clinically define the 
populations of patients with AD and MCI with biomarker positive evidence 
of amyloid pathology (MCI+) (Chapter 2). 
 
Second, I wanted to successfully exploit the [18F]AV1451 PET tracer to 
examine the extent and localization of in vivo tau pathology in AD/MCI+ 
patients and to assess the utility of this ligand as biomarker of tau pathology 
in AD (Chapter 3).  
 
Third, I aimed at evaluating the impact of in vivo tau pathology on brain 
functional connectivity, using multi-modal integration of [18F]AV1451 PET 
and rsfMRI data (Chapter 4).  
 
My fourth objective was to examine the extent and localization of in vivo 
neuroinflammation in AD/MCI+ patients using the [11C]PK11195 ligand 
(Chapter 5).  
 
Fifth, I aimed at linking this PET marker of neuroinflammation to measures 
of large-scale connectivity and aggregated indices of cognitive deficit 
(Chapter 6).  
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My thesis is based on the dataset collected within the context of the 
Neuroimaging of Inflammation in Memory and Related Other Disorders 
(NIMROD) study. The NIMROD study is a deep phenotyping cohort study, 
the aims of which include:  
 
1) the extent and patterns of in vivo tau deposition, as revealed by [18F]AV-
1451 PET ligand, in AD and other neurodegenerative disorders relatively to 
age- and sex-matched controls;  
 
2) the extent and patterns of in vivo neuroinflammation (as indexed via the 
[11C]PK11195 PET radiotracer) in patients with AD and other 
neurodegenerative disorders, relatively to age-and sex-matched control 
participants;  
 
3) how in vivo tau pathology and neuroinflammation in AD and other 
neurodegenerative disorders is linked to relevant clinical symptoms in each 
disorder (e.g., episodic memory deficits in AD);  
 
4) the relationship between in vivo tau accumulation and microglia 
activation,  
 
5) the peripheral markers of neuroinflammation (e.g., serum cytokines, T-
cell subsets) in patients with AD and other neurodegenerative disorders;  
 
6) the grey-matter and white-matter structural damage in AD and other 
neurodegenerative disorders in relation to in vivo tau accumulation and 
microglia activation;  
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7) the alterations in resting-state functional connectivity in AD and other 
neurodegenerative disorders in relation to in vivo tau pathology and 
neuroinflammation;  
 
8) the relationship between in vivo tau pathology and neuroinflammation in 
predicting longitudinal changes in cognitive decline. 
 
9) the relationship between in vivo tau pathology, neuroinflammation, and 
peripheral markers of inflammation 
 
My PhD focuses on aims 1),2),3), and 7), although in Chapter 7 (Future 
directions section), I briefly present some preliminary data, by Su Li (one 
of my NIMROD colleague) regarding aim 8).   
 
Achieving these aims has direct implications for treatment studies (both 
disease-modifying and symptomatic), healthcare planning and policy, and 
design of future researches in AD and in other neurodegenerative disorders. 
The NIMROD study comprises an extensive set of demographic, clinical, 
behavioural, PET, Magnetic Resonance Imaging (MRI) (both structural and 
functional), and serum data that can provide a long-term resource for 
studies evaluating the impact of in vivo tau deposition and 
neuroinflammation in AD and other disorders. Improved knowledge of 
disease etio-pathological mechanisms and their relationship with clinical 
markers may also provide a mean to validate preclinical models and inform 
future clinical studies.  
 
The NIMORD study gained clinical and behavioural data from various 
sources of information including the carer, patient, and clinician ratings as 
well as via the use of objective (i.e., computerized) psychological tasks and 
brain imaging measures. Patient and carer questionnaires are typically 
employed in clinical assessments and trials, enabling evaluation of potential 
inconsistencies between carer and patient rating. Objective 
neuropsychological tests and brain imaging methods were used to create a 
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bridge between preclinical and clinical research, supporting the 
development of translational models.  
 
In this chapter, I describe the methods of the NIMROD study in general, 
focusing on the cohort demographics, assessment tools, and brain imaging 
acquisition methods. The more specific analytical methods employed to 
examine the NIMROD data included in my thesis are discussed in each 
chapter.  
 
2.2. General description of the NIMROD study 
The NIMROD study protocol consists of a series of visit for brain imaging 
and behavioural evaluations as well as annual neuropsychological and 
neurological assessments over a period of 3 years (Figure 7). The baseline 
assessments are followed by one visit for MRI and then one, two or three 
visits for PET depending on the specific cohort examined.  
 
2.3. Ethical Approval & Sponsorship 
The NIMROD study was approved by the Cambridge Research Ethics 
Committee.  The study was jointly sponsored by the University of 
Cambridge and Cambridge University Hospitals Foundation NHS Trust. 
 
2.4. Locations 
The investigators were based in the Herchel-Smith Building (HSB) at the 
University of Cambridge where regional National Health Service (NHS) 
clinics for AD and non-AD disorders (e.g., progressive supranuclear palsy 
(PSP), frontotemporal dementia (FTD), and corticobasal syndrome (CBS)) 
are held. PET and MRI scans were performed at the Wolfson Brain Imaging 
Centre (WBIC) at the University of Cambridge and at the PET-CT centre on 
the Cambridge Biomedical Campus (both of which are contiguous to the 
HSB). Neuropsychological and behavioural assessments were conducted at 
the Herchel Smith Building or in participants own homes.  
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2.5. Recruitment  
Patients were recruited from the counties of Cambridgeshire, Lincolnshire, 
Bedfordshire, Norfolk, Suffolk, Hertfordshire and Essex, where participants 
were willing to travel to Cambridge for imaging studies. Recruitment relied 
on multi-source identification from primary, secondary and tertiary care, 
self-referral and relevant patient charities. Patients were recruited from 
regional specialist clinics for cognitive disorder clinics in neurology, old age 
psychiatry, and related services at Cambridge University Hospital (CUH) 
and other trusts within the regions described above. Direct referrals from 
neurological and psychiatric services were also accepted, with help from the 
National Institute for Health Research Clinical Research Network Dementias 
and Neurodegeneration Speciality (DeNDRoN) and the Join Dementia 
Research (JDR) web-based platform.  
 
Control participants were recruited from regional healthy adults who have 
indicated a willingness to participate in dementia research via JDR or 
DeNDRoN. We also recruited healthy friends and non-blood-related family 
members of the patients who were interested and willing to participate in 
research. Potential participants identified as above who showed willingness 
to take part in the research are provided with information about the study 
in the form of a patient information sheet. Following a period of time (1 
week) to consider the information, a follow-up phone call was made to 
inquire as to their interest in participation and to ask for further information 
to ensure they are eligible to take part. An appointment was then booked 
at the study premises or at participants’ home to provide an opportunity to 
ask further questions and obtain formal written informed consent from the 
participant. 
 
A personal consultee process was set up to assess the potential participation 
of patients who lacked mental capacity, in accordance with UK law. Firstly, 
their willingness to consider research participation at a level compatible with 
their cognitive abilities was evaluated. Secondly, a nominated individual 
was consulted, which included the spouse, holder of Lasting Power of 
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Attorney, IMCA, an appropriate next of kin or chosen personal consultee as 
outlined in the Mental Capacity Act (2005). All participants included in my 
thesis, including patient participants, had mental capacity. 
 
2.6. Inclusion & Exclusion criteria 
Inclusion and exclusion criteria differed depending on type of participant or 
on their clinical diagnosis. Potential participants were excluded if they had 
a concurrent major psychiatric illness (except if this is depression in the 
late-onset depression cohort) or if they had a clear contraindication to an 
MRI scan (such as a permanent pacemaker), were unable to tolerate an 
MRI (e.g., due to claustrophobia) or if they had a medical comorbidity that 
limited their ability to take part in the study (e.g. serious kidney disorders). 
Participants with previous head injury were also excluded. Potential 
participants were also excluded if they had atypical or focal parenchymal 
appearances on MRI which were not in keeping with their diagnosis (e.g., 
brain tumour or severe vascular disease). Systemic inflammatory diseases 
(e.g., lupus, rheumatoid arthritis, etc.) were also exclusion criteria as well 
as concurrent medications that might have affected the study assessments 
(e.g., chronic use of oral steroids). 
 
2.7. NIMROD participants included in my PhD studies 
1. Healthy control participants, defined as participants with MMSE scores 
>26 and with an absence of: (i) regular memory symptoms, (ii) signs or 
symptoms suggestive of dementia or (iii) unstable or significant medical 
illnesses. 
 
2. Participants with AD who meet the diagnostic criteria for probable AD as 
defined by National Institute on Aging-Alzheimer’s Association workgroups 
on diagnostic guidelines for AD (McKhann et al. 2011a). 
 
3. Participants with mild cognitive impairment (MCI), defined as participants 
having an MMSE >24 but with memory impairment beyond that expected 
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for age and education which does not meet criteria for probable AD and is 
not explained by another diagnosis (Albert et al. 2011b). The MCI patients 
did also have biomarker evidence of amyloid pathology, as assessed via 
positron emission tomography (PiB PET ligand). 
 
Once written and informed consent had been provided, participants 
performed a neuropsychological assessment using a test battery described 
in detail below. The neuropsychological battery was tailored to the cohort 
to which the participant belonged to. All participants also underwent an 
initial clinical assessment, including the collection of clinical and 
demographic information (including medication, smoking, alcohol and 
education histories). 
 
The patients with AD pathology included in my studies were in their early 
stages of their disease trajectory, although the inclusion of patients with 
MCI and biomarker evidence of amyloid pathology expanded the phenotypic 
variability of the clinical spectrum to power the analyses assessing for 
individual differences in the episodic memory problems. 
 
2.8. Brain imaging visits 
Participants attended two or four times for brain imaging depending on their 
cohort. All participants had an MRI scan. Healthy control participants 
underwent one PET scan (either with [11C]PK11195 or [18F] AV-1451). MCI 
participants had three PET scans ([11C]PK11195, [18F] AV-1451 and 
[11C]PiB) to respectively evaluate microglia activation, tau pathology and 
amyloid deposition. Participants in all other cohorts had two PET scans (for 
the DLB cohort it was [11C]PK11195 and [11C]PiB, while for AD, PSP and 
FTD cohorts it was [11C]PK11195 and [18F] AV-1451 PET scanning). 
 
Venepuncture was carried out at the time of [11C]PK11195 imaging in all 
participants to measure peripheral markers of inflammation. Each 
participant underwent repeat neuropsychological testing annually, for up to 
3 years, to provide a longitudinal assessment of cognitive function. 
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2.9. Power and Group Size Calculations 
A sample size of n=15 per each diagnostic cohort was estimated to enable 
the detection of a one standard deviation (SD) difference between groups 
with 80% power, with one SD being less than group differences in 
[11C]PK11195 binding potential in previously published studies (e.g. Edison 
et al, 2012: patients mean 0.50 (SD 0.18), controls mean 0.30 (SD 0.08); 
Iannacone et al (2012): patients mean for precuneus 0.19 (SD 0.08); 
controls 0.06 (SD 0.02)). Groups of n=15 also allowed detection of 
correlations of moderate strength (80% power for detected r=0.45 or 
greater).  Groups sizes of n=15 can robustly detect other changes 
associated with dementia, such as the extent of atrophy on MRI and 
increased [11C]PIB binding on PET imaging. 
 
2.10. Neuropsychological and Behavioural Assessment Battery 
Patients underwent a clinical assessment battery, including a semi-
structured interview for clinical history, demographic data, and 
questionnaire-based as well as detailed neuropsychological assessments of 
cognitive and behavioural changes (Figure 7). The following principles 
were applied in selecting the NIMROD test battery: 1) to employ a variety 
of tests to examine the multi-faceted cognitive deficits of different 
neurodegenerative and dementia disorders, 2) to include clinically standard 
tests as well as experimental paradigms; 3) to include questionnaires to be 
completed by patients and carers to enable complementary perspectives; 
4) to include both subjective symptom-based questionnaires and objective 
neuropsychological tests for both patients and controls, and 5) to use only 
measures that have been published and used with independent cohorts.   
 
Clinical and neuropsychological assessments were carried out either at the 
same visit or on a day of attendance for imaging. Neuropsychological follow-
up using the same battery of tests was undertaken annually for up to 3 




Figure 7: Flow chart showing participants‘ journey through the NIMROD study.  
AD, Alzheimer’s disease; MCI, mild cognitive impairment; DLB, dementia with Lewy 
bodies; PDD, Parkinson’s disease dementia; PSP, progressive supranuclear palsy; FTD, 
frontotemporal dementia; LLD, late life depression; MRI, magnetic resonance imaging; 
PET, positron emission tomography. 
 
2.11. PET acquisition protocol 
PET scanning was performed either on a GE Advance PET scanner (GE 
Healthcare, Waukesha, WI) at the WBIC or in the GE Discovery 690 PET/CT 
scanner at Addenbrooke’s hospital. The number of patients and controls 
across both scanners were equally distributed. A 15 minutes 68Ge/68Ga 
transmission scan was used for attenuation correction on the Advance, 
which was replaced by a low dose computed tomography (CT) scan on the 
Discovery 690. The emission protocols were the same on both scanners.  
 
The radiotracers were produced at the WBIC Radiopharmaceutical 
Chemistry laboratories with high radiochemical purity (>95%). 
[18F]AV1451, [11C](R)-PK11195 and [11C]PiB were produced using the GE 
PET trace cyclotron, a 16 MeV proton and 8 MeV deuteron accelerator. The 
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production of [18F]AV1451 was based on the synthetic methods developed 
by Avid Radiopharmaceuticals and modified to use the GE TracerLab FX-FN 
synthesizer at WBIC. [11C](R)-PK11195 were prepared using the 
‘Disposable’ synthesis system or GE TRACER laboratory FX-C module. 
[11C]PiB was prepared using the GE TRACER laboratory FX-C module. All 
PET radiotracers detailed information is displayed in Table 2.  
 
2.11.1. [18F]AV1451 
[18F]AV1451 radioligand was selected to evaluate the density of tau 
deposits. 370MBq of [18F]AV1451 was injected intravenously over 30 
seconds at the onset of a 90 minutes scan, with emission data subsequently 
reconstructed into 58 contiguous time frame (18x5, 6x15, 10x30, 7x60, 
4x150 and 13x300 seconds) images for kinetic analysis with the simplified 
reference tissue model.  
 
2.11.2. [11C]PiB 
[11C]PiB PET specifically binds to fibrillar amyloid-beta plaques. It indicates 
the presence of AD pathology, and increases the likelihood that participants 
with MCI at baseline will clinically convert to AD over time (Okello et al. 
2009b). 550MBq of [11C]PiB were injected as a bolus followed by PET 
imaging from 40-70 minutes post-injection, providing imaging data suitable 
for subsequent standardised uptake value ratio (SUVR) analysis 
 
2.11.3. [11C](R)-PK11195 
[11C](R)-PK11195 radioligand aimed to measure the density of activated 
microglia as an indication of neuroinflammation. 500MBq [11C](R)-PK11195 
was injected intravenously over 30 seconds at the onset of a 75 minutes 
scan, with emission data subsequently reconstructed into 55 contiguous 
time frame (18x5, 6x15, 10x30, 7x60, 4x150 and 10x300 seconds) images 
for kinetic analysis with the simplified reference tissue model.  
 










at the end of 
synthesis 
(GBq/μmol) 




370 500 550 
PET duration 
(minutes) 
90 75 45 
Frame images 58 55 1 
Cohorts PSP, AD, MCI 
and healthy 
control 








Table 2: NIMROD PET radiotracers and study groups.   
Abbreviations: PET, Positron Emission Tomography; GBq, Gigabecquerel; MBq, 
Megabecquerel; PSP, Progressive Supranuclear Palsy; AD, Alzheimer’s disease; MCI, Mild 
Cognitive Impairment.  
 
 
More than one PET scan was required in patient groups to allow direct 
comparison between tau, amyloid, and inflammation. Two healthy control 
groups were recruited in order for them to prevent excessive radiation 
exposure; therefore one group took a [18F]AV1451 PET session and the 
other healthy cohort attended  [11C](R)-PK11195 PET scan instead.   
 
2.12. PET data pre-processing  
Each PET emission frame was reconstructed using the PROMIS 3-
dimensional filtered back projection algorithm into a 128 x 128 matrix 30cm 
trans-axial field of view, with a trans-axial Hann filter cut-off at the Nyquist 
frequency (Kinahan & Rogers 1989a). Corrections were applied for random 
movements, dead time, normalization, scatter, attenuation, and sensitivity.  
 
Each emission image series was realigned using SPM8 to correct for patient 
motion during data acquisition (www.fil.ion.ucl.ac.uk/spm/software/spm8) 
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and create a mean image. In cases of very large movement (>10mm in 
translation or >10 degrees of rotation; this applied for 10% of the cases) 
the SPM co-registration function was used. Every dynamic frame after 1 
minute post-injection was co-registered to the first minute frame. This 
process was repeated until the motion was corrected. The mean aligned PET 
image was rigidly co-registered to the MRI T1-weighted image using SPM8 
and the inverse transformation applied to the modified Hammers atlas to 
put it in native PET space. Kinetic modelling was then performed on the 
motion-corrected time series in the cases of [18F]AV1451 and [11C](R)-
PK11195. Reference regions were required for the kinetic modelling 
analysis.  
 
For [18F]AV1451, the reference region was defined in the superior grey-
matter of the cerebellum using a 90% grey-matter threshold on the grey-
matter probability map produced by SPM8 smoothed to PET resolution. The 
superior cerebellum was used as reference region as it is considered to have 
little or no tau pathology in AD/MCI+ (Okello et al. 2009c; Scholl et al. 
2016a; Schwarz et al. 2016a). This was confirmed in our post mortem cases 
(see supplementary material published in (Passamonti et al. 2017b).  
 
In the case of [11C](R)-PK11195, it is well known that it is difficult to identify 
a suitable reference region; therefore, supervised cluster analysis was used 
to determine the reference tissue time-activity curve (Yaqub et al. 2012). 
Supervised cluster analysis was designed to extract pure grey matter signal. 
Yaqub and collegues (2012) demonstrated that the supervised cluster 
analysis with 4 kinetic classes (grey, white, blood and high specific binding 
(HSB)) performs better than 6 kinetic classes (grey, white, bone, soft 
tissue, blood and HSB). In order to extract the reference time activity curve 
(TAC), each voxel TAC of the scan was analyzed using the set of predefined 
kinetic classes to find the scaling coefficient of each kinetic class, so that 
the total TAC is equal to the sum of these scaled kinetic classes. A non-
negative least squares algorithm was used for finding the scaling 
coefficients (Turkheimer et al. 2000). Scaling coefficients of each kinetic 
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class were stored in coefficient maps showing their spatial distribution. 
Finally, to extract the reference tissue TAC, the coefficient map from the 
(normal) grey-matter kinetic class was used to calculate the weighted 
average, as follows: 
 
𝐶𝑡










where, N is the number of voxels, 𝐶𝑡
𝑟𝑒𝑓
 the resulting reference tissue TAC, 
𝑤𝑖
𝑔𝑟𝑒𝑦
 the grey scaling coefficient and 𝐶𝑡
𝑣𝑜𝑥𝑒𝑙 the voxel TAC. 
 
[18F]AV1451 and [11C](R)-PK11195 non-displaceable binding (BPND) was 
determined for each Hammers atlas ROI using a basis function 
implementation of the simplified reference tissue model (SRTM) operating 
upon the dynamic Hammers atlas and reference tissue ROI data, both with 
and without CSF correction (Gunn et al. 1997). CSF partial volumes were 
calculated by division with the mean ROI probability (normalized to 1) of 
grey and white matter segments, each smoothed to PET resolution. To test 
whether correction for CSF affected the main results, we repeated all the 
[18F]AV1451 and [11C](R)-PK11195 PET analyses using data not corrected 
for CSF (see chapter 3 and 5).   
 
[11C]PiB data were quantified using standardized uptake value ratio (SUVR) 
by dividing the static image by mean radioactivity concentration of the 
reference tissue region defined by >90% of the superior cerebellum. 
[11C]PiB data were treated as dichotomous measures (i.e., positive or 
negative MCI) and considered MCI positive if the average SUVR value across 
the cortical ROIs was > 1.52 (Hatashita & Yamasaki 2013). 
 
2.13. MRI acquisition protocol  
MRI scanning was carried out at the Wolfson Brain Imaging Centre (WBIC) 
using 3 T Siemens scanners. The following sequences were used during the 
scanning protocol: 
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1. Three-dimensional structural high-resolution T1-weighted sequence 
examining for structural brain abnormalities (176 slices of 1.0 mm 
thickness, first echo time (TE)=2.98 ms, repetition time (TR =2300 ms, flip 
angle=9°, acquisition matrix 256x240; voxel size=1x1x1 mm3). 
 
2. Perfusion (pulsed arterial spin labelling) for blood flow (9 slices of 8.0 
mm thickness, TE=13 ms, TR=2500 ms, acquisition matrix 64x64; voxel 
size=4x4x8 mm3, inversion time 1=700 ms, inversion time 2=1800 ms). 
 
3. Diffusor tensor imaging (DTI) to obtain fractional anisotropy measures 
of white matter integrity and gross axonal organisation (63 slices of 2.0 mm 
thickness, 63 diffusion directions, TE= 106 ms, TR=11 700 ms, b-value 1=0 
s/mm2, b-value 2=1000 s/mm2, acquisition matrix 96x96; voxel 
size=2x2x2 mm3). 
 
4. Susceptibility-weighted imaging (SWI) to identify microhaemorrhages, 
venous blood and iron deposition (40 slices of 2.0 mm thickness, TE=20 
ms, TR=35 ms, flip angle=17°, acquisition matrix 256x240; voxel 
size=1x1x2 mm3). 
 
5. High-resolution hippocampal subfield sequences carried out in coronal T2 
for smaller structural changes in the hippocampus (20 slices of 2.0 mm 
thickness, TR=6420 ms, flip angle=160°, acquisition matrix 512x408; voxel 
size=0.4x0.4x2 mm3). 
 
6. Resting state functional MRI with pulse and breathing monitored to 
examine ‘task-free’ functional brain connectivity (34 slices of 3.8 mm 
thickness, TE=13 ms, TR=2430 ms, flip angle=90°, acquisition matrix 
64x64; voxel size=3.8x3.8x3.8 mm3, duration 11 min and 5 s). 
 
7. T2 Fluid Attenuated Inversion Recovery (FLAIR) for characterising 
periventricular lesions adjacent to the sulci and white matter lesions and 
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hyperintensities (75 slices of 2 mm thickness, TE=132 ms, TR=12 540 ms, 
flip angle=120°, acquisition matrix 256x256; voxel size=0.9x0.9x2 mm3). 
 
All images were reviewed by a Consultant Radiologist at CUH to exclude 
unexpected brain abnormalities in participants. None of the participants 
recruited in the NIMROD study showed significant abnormalities.  
 
2.14. MRI data pre-processing 
2.14.1. Structural MRI analytical pipeline  
The T1-weighted images were used to facilitate tissue class segmentation 
(grey- and white-matter, together with cerebro-spinal fluid; CSF), and to 
allow inverse normalisation of template space regions of interest (ROIs) 
defined by modified Hammers atlas to subject MRI space (Hammers et al. 
2003). The left and right ROIs were combined in the AD and PSP clinical 
cohorts based on the fact that these diagnostic groups do not show any 
laterality of the clinical symptoms. The brainstem of the atlas was split into 
midbrain (z ≥ 22mm), pons (z ˂ -22mm) and medulla oblongata (z = -
49mm). Each T1 image was non-rigidly registered to the ICBM2009a 
template brain using ANTS (http://www.picsl.upenn.edu/ANTS/) with 
default settings, and the inverse transform was applied to the modified 
Hammers atlas (resliced from MNI152 to ICBM2009a space) to bring the 
ROIs to subject MRI space.  
 
2.14.2. Functional MRI analytical pipeline  
The first six volumes were discarded to eliminate saturation effects and 
achieve steady-state magnetization. Pre-processing of resting-state data 
employed the Multi-Echo Independent Components Analysis (ME-ICA) 
pipeline, which  uses  independent  component  analysis  to  classify blood 
oxygenation dependant (BOLD) and non-BOLD signals based on the 
identification of linearly dependent and independent echo-time related 
components (https://wiki.cam.ac.uk/bmuwiki/MEICA) (Kundu et al. 
2013a).  
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The ME-ICA pipeline provides an optimal approach to correct for movement-
related and non-neuronal signals, and is therefore particularly suited to our 
study, in which systematic differences in head position might have been 
expected between groups. After ME-ICA, the data were smoothed with 6 
mm full-width half maximum kernel. 
 
The location of the key cortical regions in each network was identified by 
spatial independent component analysis (ICA) using the Group ICA of fMRI 
Toolbox (Calhoun et al. 2001a) in an independent dataset of 298 age-
matched healthy individuals from the population-based cohort in the 
Cambridge Centre for Ageing and Neuroscience (Cam-CAN) (Shafto et al. 
2014a). Details about pre-processing and node definition are published 
previously (Tsvetanov et al. 2016a). Four networks were identified by 
spatially matching to pre-existing templates (Shirer et al. 2012a). The 
default mode network contained five nodes: the ventromedial prefrontal 
cingulate cortex, dorsal and ventral posterior conjugate cortex, and right 
and left inferior parietal lobes. The fronto-parietal network was defined 
using bilateral superior frontal gyrus and angular gyrus. Subcortical nodes 
included nodes like the bilateral putamen and hippocampus. The node time-
series were defined as the first principal component resulting from the 
singular value decomposition of voxels in a 8-mm radius sphere, which was 
centred on the peak voxel for each node (Tsvetanov et al. 2016a). 
 
After extracting nodal time-series we sought to reduce the effects of noise 
confounds on functional connectivity effects of node time-series using a 
general linear model (Geerligs et al. 2017). This model included linear 
trends, expansions of realignment parameters, as well as average signal in 
the white-matter and cerebrospinal, including their derivative and quadratic 
regressors from the time-courses of each node (Satterthwaite et al. 2013).  
 
The signals in the white-matter and cerebrospinal fluid were created by 
using the average across all voxels with corresponding tissue probability 
larger than 0.7 in associated tissue probability maps available in the SPM12 
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software (http://www.fil.ion.ucl.ac.uk/spm/software/spm12/). A band-pass 
filter (0.0078-0.1 Hz) was implemented by including a discrete cosine 
transform set in the general linear model, ensuring that nuisance regression 
and filtering were performed simultaneously (Hallquist et al. 2013; 
Lindquist et al. 2018).  
 
The general linear model excluded the initial five volumes to allow for signal 
equilibration. The total head motion for each participant, which was used in 
subsequent between-subject analysis as a covariate of no interest (Geerligs 
et al. 2017), was quantified using the approach reported in Jenkinson and 
colleagues (Jenkinson et al. 2002a), i.e. the root mean square of volume-
to-volume displacement. Finally, the functional connectivity between each 





Chapter 3| 18F-AV-1451 PET to assess in 




In this Chapter, I describe part of the results of my published study 
(Passamonti et al. 2017a), in which I sought to evaluate the utility of the 
18F-AV-1451 PET tracer in assessing tau pathology in Alzheimer’s disease 
(AD).  
 
In AD, oligomeric and aggregated neurofibrillary tau tangles are one the 
major determinant of synaptic/cell dysfunction and death (Goedert et al. 
1988; Ballatore et al. 2007; De Calignon et al. 2012), notwithstanding the 
importance of β-amyloid in its ‘toxic alliance’ with pathological tau (Bloom 
2014). The intensity and distribution of tau in AD also correlates with the 
clinical syndrome and severity and has been considered as one of the 
primary factors in the neuropathological staging of AD (Braak et al. 2006b; 
Murray et al. 2014; Ossenkoppele et al. 2015b). To be able to quantify the 
burden and distribution of tau pathology in living patients, or those at high 
risk of developing tau-related disorders is a major step forward in the 
development of disease modifying therapies targeting the tau protein.  
 
Different PET radioligands have been developed to measure in vivo binding 
to aggregated tau, including PBB3 (Maruyama et al. 2013a), a series of 
‘THK’ compounds (Okamura et al. 2013b), and [18F]AV1451 (Chien et al. 
2013; Xia et al. 2013). In autoradiographic studies with post mortem 
human brain tissues, the radiotracer [18F]AV1451 colocalizes selectively 
with hyperphosphorylated tau over β-amyloid plaques (Marquié et al. 
2015), although off-target binding and lack of sensitivity to non-AD tau 
pathology has been described since they initial study by Chien and 
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colleagues (Marquie et al. 2015). In our NIMROD study we chose to use 
[18F]AV1451, which have had the most extensive evidence internationally 
at the time when the data of my thesis were collected. Subsequently, the 
severity of displacement of THK5351 by selegiline (acting on MAO-B), and 
lack of large scale data with PBB3, have had left [18F]AV1451 the lead 
compound despite its controversies, while second generation ligands are 
still developed and validated.  
 
In patients with MCI and AD, there is higher [18F]AV1451 non-displaceable 
binding potential (BPND), a measure of specific binding, in parietal and 
temporal cortices relative to age-matched healthy controls (Okello et al. 
2009b). Progressively increasing regional [18F]AV1451 binding in AD has 
also been associated with Braak staging of neurofibrillary tau pathology 
(Schöll et al. 2016; Schwarz et al. 2016b), while [18F]AV1451 PET binding 
patterns mirror the clinical and neuroanatomical variability in the AD 
spectrum (Ossenkoppele et al. 2016a).  
 
Specifically, patients with the amnestic presentation of AD (as those 
included in my thesis) showed the highest [18F]AV1451 uptake in medial 
temporal lobe regions such as the hippocampus, amygdala, and 
parahippocampal cortex, while patients with the logopenic variant of AD 
displayed increased left hemispheric [18F]AV1451 binding, particularly in 
posterior temporoparietal areas implicated in linguistic processes 
(Ossenkoppele et al. 2016a). Performance on domain-specific 
neuropsychological tests was also associated with increased [18F]AV1451 
uptake in brain regions involved in episodic memory, visuospatial skills, and 




3.2. Main aims and hypotheses 
The main aim of the study described in this chapter was to test two 
hypotheses:  
 
1) that patients with AD and MCI+ show increased [18F]AV-1451 binding in 
cortical and sub-cortical areas typically associated with AD pathology, 
including the medial temporal lobe as well as parietal and lateral temporal 
cortices (Serrano-Pozo et al. 2011). 
 
2) that higher [18F]AV-1451 in these brain regions positively relate to 
cognitive impairment as assessed via the Addenbrooke’s Cognitive-
Examination score-revised, MMSE, and Ray-Auditory Verbal Learning Test 
(RAVLT). 
 
3.3. Participants and Methods 
3.3.1. Participants 
Nine patients meeting diagnostic criteria for probable AD (McKhann et al. 
2011b), and six patients with MCI and biomarker evidence of AD (i.e., 
amyloid pathology) were included in this study. All participants with MCI 
had a positive Pittsburgh compound B (PiB) PET scan (assessing in vivo 
amyloid pathology).  
 
Thirteen age- and sex-matched healthy controls with no history of major 
psychiatric or neurological illnesses, head injury or any other significant 
medical co-morbidity were also included to allow group-wise comparisons 
with the AD cohort.   
 
All participants were aged over 50 years, had sufficient proficiency in 
English for cognitive testing and had no contraindications to magnetic 
resonance imaging (MRI). 
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3.3.2. PET imaging  
3.3.2.1. PET pre-processing 
Each emission frame was reconstructed using the PROMIS 3-dimensional 
filtered back projection algorithm into a 128x128 matrix 30cm trans-axial 
field of view, with a trans-axial Hann filter cut-off at the Nyquist frequency. 
Corrections were applied for randoms, dead time, normalization, scatter, 
attenuation, and sensitivity. Each emission image series was aligned using 
SPM8 to correct for patient motion during data acquisition 
(www.fil.ion.ucl.ac.uk/spm/software/spm8). 
 
The mean aligned PET image, and hence the corresponding aligned dynamic 
PET image series, was rigidly registered to the T1-weighted image using 
SPM8 to extract values from both the Hammers atlas regions of interest 
(ROIs) and those in a reference tissue defined in the superior grey-matter 
of the cerebellum using a 90% grey-matter threshold on the grey-matter 
probability map produced by SPM8 smoothed to PET resolution. The 
superior cerebellum was used as reference region as it is considered to have 
little or no tau pathology in AD (Okello et al. 2009d). All ROI data, including 
the reference tissue values, were corrected for cerebrospinal fluid (CSF) 
partial volumes through division with the mean ROI probability (normalized 
to 1) of grey + white matter segments, each smoothed to PET resolution. 
To test whether correction for CSF affected the main results, we repeated 
all the [18F]AV-1451 PET analyses using data not corrected for CSF.  
 
3.3.2.2. PET statistical analyses 
To compare [18F]AV-1451 binding across groups (AD/MCI+ and controls), 
individual ROI binding values for [18F]AV-1451 were used in a repeated-
measures general linear model (GLM) to test for the main effect of ROI, 
main effect of group, and group x ROI interaction.  
 
Age and education were included as covariates of no interest. For the 
AD/MCI+, I also tested for correlations between regional [18F]AV-1451 
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binding and cognitive impairment using the ACE-R and MMSE scores with 
Pearson’s correlation (with partial correlations accounting for variability in 
age and education).  
 
3.4. Results 
3.4.1. Participants  
As expected, patients with AD and MCI+ demonstrated cognitive 
impairment compared to controls, as measured by the Addenbrookes’ 
Cognitive Examination-Revised test (ACE-R), mini-mental status 
examination (MMSE), and Ray-Auditory Verbal Learning Test (RAVLT) 
(Table 3). 
Table 3: Participants’ demographic and clinical details (tau PET study). 
Participant details (mean, with standard deviation (SD) and range in parentheses) and 
group differences by one-way analysis of variance or chi-squared test. AD/MCI+: 
Alzheimer’s disease/mild cognitive impairment (amyloid positive from Pittsburgh 
Compound-B, PiB, positron emission tomography scan); MMSE: Mini Mental State 
Examination; ACE-R: Addenbrookes’ Cognitive Examination, Revised. N/S, not significant 
at P<0.05 (uncorrected). 
 
Next, I examined the demographic and clinical characteristics of the 
patients with clinically probable AD, relative to MCI+ patients and controls. 
Demographic & Clinical 
data 
AD / MCI+ (n=15) Controls (n=13) Group 
difference 
Sex (males/females) 9/6 6/7 N/S 
Age (years) (SD, range) 71.6 (±8.7, 54-85) 67.2 (±7.3, 55-
80) 
NS 
Education (years) (SD, 
range) 
13.8 (±3.1, 10-19) 13.1 (±1.7, 10-
18) 
NS 










RAVLT (SD, range) 1.3 (±1.4, 0-4) 10.7 (±2.8, 4-16) F=11.6,P<0.00
01 
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Table 4 shows that clinically probable AD patients were similar to MCI+ 
patients in terms of demographic and clinical features. 
 
Table 4 Demographic & clinical details in AD, MCI+, and controls (tau PET study). 
Participant details (mean, with standard deviation (SD) and range in parentheses) and 
group differences by one-way analysis of variance or chi-squared test. AD: clinically 
probable Alzheimer’s disease; /MCI+: mild cognitive impairment (amyloid positive from 
Pittsburgh Compound-B, PiB, positron emission tomography scan); MMSE: Mini Mental 
State Examination; ACE-R: Addenbrookes’ Cognitive Examination, Revised. N/S, not 
significant at P<0.05 (uncorrected). 
 
3.4.2. [18F]AV-1451 binding in Alzheimer’s disease 
The mean [18F]AV-1451 PET map in each group (Figure 8) and quantitative 
region of interest (ROI) analyses (Figure 9), indicated high [18F]AV-1451 
binding in the basal ganglia in both groups including controls.  
 
In the repeated-measures GLM of regional binding, we found a significant 
main effect of group (F=17.5, P=0.00001), and a ROI x group interaction 
(F=7.5, P<0.00001), although there was no main effect of ROIs, even 
considering the binding values in the ‘hot-spot’ ROIs (basal ganglia 
including caudate, putamen, and pallidum) (F=0.8, P=0.8) (Figure 9).  
 
Demographic & Clinical 
data 




Sex (males/females) 2/7 4/2 6/7 N/S 
Age (years) (SD, 
range) 






























RAVLT (SD, range) 0.9 (±1.3, 0-4) 1.2 (±1.2, 0-3) 10.7 (±2.8, 4-16) F=10.4, 
P<0.001 
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The group and interaction effects were driven by higher [18F]AV-1451 
binding in the AD/MCI+ group relative to controls, in frontal, parietal, lateral 
temporal, and occipital cortices as well as in the hippocampus and other 
medial temporal lobe ROIs (post-hoc t-tests, T’s>2.2, P’s<0.04) (Figure 
9).  
Next, I examined the [18F]AV-1451 ROI binding in AD and MCI+ groups 
separately, relative to controls, with the caveat of the small sample size in 
each group of patients (AD=9, MCI+=6). Nevertheless, there were still 
group and interaction effects that were driven by higher [18F]AV-1451 
binding in the patients’ groups relative to controls (F=4.3, P<0.001), 
although the difference between AD and MCI+ patients were not significant 
(post-hoc t-tests, T’s<1.3, P’s>0.1) (Figure 10).  
 
 
Figure 8: [18F]AV-1451 findings in AD/MCI+ and controls (voxel-wise data). 
Mean [18F]AV-1451 positron emission tomography map in each group. Note the overall 
high [18F]AV-1451 binding in the basal ganglia in both groups including controls. Patients 
with Alzheimer’s disease (AD) pathology showed increased [18F]AV-1451 binding in the 
medial temporal lobe regions and other cortical areas, relative to controls (see Figure 10 
for quantitative analyses in each region of interest (ROI)). 
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Figure 9: [18F]AV-1451 findings in AD/MCI+ and controls (ROI analyses). 
Mean (± standard error) [18F]AV-1451 non-displaceable binding potential (BPND) in each 
region of interest (ROI) for the following participant groups: Alzheimer’s disease (AD) and 
amyloid positive mild cognitive impairment (MCI+); healthy controls (HC). The [18F]AV-




Figure 10: [18F]AV-1451 findings in AD, MCI+, and controls (ROI analyses). 
Mean (± standard error) [18F]AV-1451 non-displaceable binding potential (BPND) in each 
region of interest (ROI) for the following participant groups: clinically probable Alzheimer’s 
disease (AD), amyloid positive mild cognitive impairment (MCI+); healthy controls (HC). 
The [18F]AV-1451 BPND data showed in this figure are corrected for cerebrospinal fluid 
(CSF) volume.  
 
Repeating the same analyses using [18F]AV-1451 binding values that were 
not corrected for CSF partial volume effects yielded similar results (F=1.1, 
P=0.2, for the main effect of ROIs; F=16.7, P<0.00001 for the main effect 
of group; and F=6.3, P<0.00001 for the group x ROI interaction).  
This analysis demonstrates that our main findings were robust against 
between-groups effects that might have been driven by differences in grey-
matter atrophy between patients and controls. 
 
3.4.3. [18F]AV-1451 binding and AD cognitive deficit 
Next, I tested whether the regional [18F]AV-1451 binding related to 
cognitive deficit as assessed via the ACE-R, MMSE, and Rey-Auditory Verbal 
Learning (RAVLT) scores. In the AD/MCI+ group, there was no significant 
correlation between ACE-R, MMSE or RAVLT scores and [18F]AV-1451 
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binding in any ROI (P’s>0.14). These null results were also found when the 
correlation analyses between ACE-R, MMSE or RAVLT scores and [18F]AV-
1451 binding was repeated for the clinically probable AD and the MCI+ 
groups, separately (P’s>0.23).  
Repeating the correlation analyses when using the [18F]AV-1451 
binding values that were not corrected for CSF volume also yielded non-
significant results (P’s>0.1). 
 
3.5. Discussion  
This study shows that PET imaging with the radiotracer 18F-AV-1451 can 
reveal distinct patterns of tau pathology in AD and its prodromal state of 
MCI, in comparison to healthy controls. However, despite the potential of 
18F-AV-1451 as biomarker of tau pathology in AD, caution in the 
interpretation of its binding targets is indicated by our current and previous 
studies (Marquie et al. 2015). In particular, high levels of non-specific 
binding were detected in the basal ganglia of patients with AD as well 
healthy controls. Different unspecific targets for the 18F-AV-1451 tracer 
have been proposed and these include neuromelanin, ferritin, other iron-
related proteins or the MAO enzyme (Marquie et al. 2015).  
 
However, some of these ‘off-target’ sites of 18F-AV-1451 as the 
neuromelanin binding can only be expected in certain brain regions that 
contain neuromelanin (e.g., the substantia nigra). Neither the basal ganglia 
or the cortical mantle have neuromelanin deposits so the neuromelanin 
hypothesis of the 18F-AV-1451 ‘off-target’ binding cannot explain the high 
unspecific binding that we and others observed in vivo in the basal ganglia 
(see Figure 9).  
 
An alternative explanation is that 18F-AV-1451 unspecifically binds to the 
MAO-A enzyme that is significantly expressed in the basal ganglia (Ng et al. 
2017), although displacement studies to test this hypothesis have not been 
conducted yet.  
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Over and above the clarification of its off-target binding properties, there is 
nowadays robust evidence from longitudinal studies that changes in 
[18F]AV-1451 binding over time relate to progressive accumulation and 
spreading of tau pathology in AD as well as to cognitive decline. This 
reinforces the use of [18F]AV-1451 PET as a clinically useful biomarker to 
track tau pathology and disease progression in AD (Harrison et al. 2019; 
Pontecorvo et al. 2019). At the time of the data collection for my thesis, a 
cross-sectional study like ours could not be used to infer such important 
longitudinal changes in tau pathology.  
 
Nevertheless, our understanding of in vivo tau pathology and 
neuroinflammation in AD will greatly benefit from longitudinal and 
interventional studies. Some of these studies have already been conducted 
while others are underway. Amongst these, two prominent studies have 
clearly shown that in vivo tau accumulation (as assessed via [18F]AV1451 
PET imaging) increases over time as AD progresses (Harrison et al. 2019; 
Pontecorvo et al. 2019). Interestingly these PET-tracked tau changes in 
relation to disease severity follow the pathologically well-established Braak 
staging (Jack et al. 2018; Lowe et al. 2018). These are promising studies 
that reinforce the value of using [18F]AV1451 PET as biomarker of AD and 
support its intrinsic ability to objectively assess the high individual 
difference in disease progression that is present in the AD clinical spectrum.  
 
In contrast to previous studies (Johnson et al. 2016; Ossenkoppele et al. 
2016b), our [18F]AV-1451 data did not correlate with severity of cognitive 
impairment in the MMSE and ACE-R tests. Although there can be several 
reasons for null results, this may be due to lack of statistical power (type II 
error) or the use of clinical measures that were not sensitive enough to 
describe the full spectrum of clinical variability in AD.  
 
Technical limitations should also be discussed. In particular, our PET 
analyses used ‘partial volume’ corrections that derived from the amount of 
cerebrospinal fluid (CSF) volume included in each ROI. Although this 
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attenuates the potential effect of AD-related brain atrophy, at the same 
time, this analytical procedure might induce an over-correction of the data 
that could in turn inflate the size of the statistical effects. To avoid the 
potential over-correction of the PET binding values, I have therefore re-run 
the analyses using the uncorrected PET data which reassuringly yielded to 
similar results in terms of the main effect of group and group x ROI 
interaction.  
 
Interestingly, the brain regions in which I identified the most significant 
group differences in [18F]AV-1451 binding in AD, relative to controls, were 
those predicted from the specific patterns of AD-related neuropathology. In 
particular, patients with clinical probable AD and amyloid positive MCI 
displayed increased [18F]AV-1451 binding in a widely distributed group of 
sub-cortical and cortical regions that have been repeatedly implicated in the 
pathophysiology of AD (e.g., hippocampus, medial temporal lobe as well as 
parietal and lateral temporal cortices)(Braak & Braak 1995; Braak et al. 
2006a).  
 
In conclusion, the [18F]AV-1451 tracer is a potentially useful PET ligand for 
clinical and non-clinical research in AD, despite its non-specific “off-target” 
binding which remains to be clarified and quantified. Overall, my and other 
studies support the use of [18F]AV-1451 PET ligand for further research in 
AD and related neurodegenerative disorders. 
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Chapter 4 | Tau burden & network 
dysfunction in Alzheimer’s disease 
 
4.1. Introduction  
In this chapter, I examine the relationship between in vivo tau pathology 
and brain functional connectivity by combining PET imaging with the ligand 
[18F]AV-1451 and graph theoretical measures derived from ‘task-free’ 
functional magnetic resonance imaging (fMRI) data.  
 
In Alzheimer’s disease (AD), neuropathology and atrophy are most marked 
in those brain regions that are densely connected, both at the structural 
(Crossley et al., 2014) and functional level (Dai et al., 2014). In other 
words, these densely connected regions are usually referred to as ‘hubs’ 
(Buckner et al., 2009). There are a number of hypotheses as to why hubs 
are vulnerable to neurodegeneration. First, pathological proteins may 
propagate trans-neuronally, in a prion-like manner (Prusiner, 1984; Baker 
et al., 1994; Goedert, 2015) such that highly connected regions are more 
likely to receive pathology from ‘seed’ regions affected in early stages of 
the disease (Zhou et al., 2012), leading to neurodegeneration that mirrors 
structural and functional brain connectivity (Raj et al., 2012, 2015; 
Abdelnour et al., 2014).  
 
In addition, hubs might be selectively vulnerable to a given level of 
pathology, due to a lack of local trophic factors (Appel, 1981). 
 
The trans-neuronal spread hypothesis predicts that regions that are more 
strongly interconnected would accrue more tau pathology. This would 
manifest as higher tau burden in nodes with larger weighted degree, which 
is a measure of the number and strength of functional connections involving 
each node.  
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However, if trophic support is an important factor in tau accumulation, this 
might manifest as a negative relationship between tau burden and 
connectivity measures; in other words, nodes with less tightly clustered 
connectivity patterns might have more vulnerable trophic supply. 
 
In this study we examine, in the same subjects, the relationship between 
in vivo tau burden, as measured by the PET ligand 18F-AV-1451 BPND, and 
functional connectivity, as summarized by graph theoretic measures based 
on resting state (task-free) functional MRI.  
 
I now introduce the graph analysis mathematical framework that has been 
used to quantify the brain connectivity measures employed in this study 
and to test the hypotheses stated in section 4.2. 
 
4.1.1. Graph analysis to measure network function  
In recent years, there has been a growing interest in describing the brain 
functioning by using theoretical frameworks that can formally model the 
complexity of the neural connectivity patterns. Within this context, 
mathematical approaches based on graph theory have been applied to 
measure the architecture (‘topology’) of the brain functional connectivity 
patterns (i.e., ‘connectomic’ approach) (Fornito & Bullmore, 2015). 
 
This graph theoretical approach provides a series of key indices to quantify 
different aspects of the brain ‘connectome’ (Fornito & Bullmore, 2015). For 
instance, the network’s capacity to ‘route’ information across its distinct 
elements (‘nodes’ or brain areas) can be estimated by computing the 
efficiency of the paths (‘edges’) linking these nodes (Boccaletti, Latora, 
Moreno, Chavez, & Hwang, 2006).  
 
In other words, a network’s efficiency is a quantitative representation of the 
average number of steps it would take for information to ‘travel’ across the 
network. Higher efficiency reflects fewer steps needed to route information 
from A to B. The standard graph metric of efficiency does not directly 
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indicate metabolic costs, time taken, network capacity, or data corruption, 
although these factors can be considered in more complex graphs. 
Measures of efficiency are most informative about integration within a 
network. Related measures can be applied at the global or local level 
(Rubinov & Sporns, 2010).  
 
Graph analyses also enable one to quantify the degree of segregation within 
a network. For example, networks may comprise a set of modules, within 
which there is strong connectivity but between which there is selective 
connectivity (modularity). The clustering of small sets of nodes, and the 
degree to which two connected nodes are both connected to a third node, 
also confer particular properties to a network, that we shall see are relevant 
to the vulnerability and impact of neurodegeneration (i.e., global or local 
clustering coefficient).  
 
Studying the connectome’s relationship to in vivo tau pathology in dementia 
has thus the potential to test hypothesis of functional brain mechanisms 
underlying AD; and to quantify the effect of pathology the connectome. This 
study associates the molecular tau pathology in AD, as assessed via 
[18F]AV-1451 PET imaging, with functional connectivity patterns across 
large-scale networks, as measured via resting-state fMRI (rsfMRI). 
 
4.1.2. Graph-measures of connectivity  
A pictorial representation of the graph indices employed in this chapter is 
provided in Figure 11. Note the distinction between measures that relate 
to nodes and to edges, and the distinction between global network 
measures and local properties. The graph metrics that we assessed in this 
study were the following: 
 
1) Weighted degree: the number and strength of functional connections 
involving each node. 
 
2) Betweenness centrality: the number of shortest paths between any other 
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two nodes that pass through the node of interest. Nodes that are important 
for the transfer of information between other nodes have high betweenness 
centrality. 
 
3) Closeness centrality: the inverse of the path length between a node and 
all other nodes in the graph. This is the node-wise equivalent of global 
efficiency, which is the inverse sum of all the shortest path lengths in the 
graph. 
 
4) Local efficiency: the number of strong connections a node has with its 
neighbouring nodes. This reflects the robustness of local networks to 
disruption. 
 
5) Eigen-centrality: this measure quantifies the functional influence of a 
node on every other node in the graph, by weighting the importance of each 
nodal connection based on the influence of the nodes with which they 
connect. 
 
Nodal connectivity strength was assessed for comparison to weighted 
degree, to ensure that our results did not result from bias introduced by 
proportionate thresholding. This metric is related to weighted degree but 
includes information from all strengths of connection between every pair of 
nodes. As such, it is more subject to functional MRI signal-to-noise ratio 
limitations, and it is not a suitable metric for whole-brain, cross-sectional 
analysis across individuals, but it can be used to make a node-wise, group 
average assessment analogous to that for weighted degree. 
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Figure 11: Pictorial representation of graph-analysis connectivity metrices. 
Top row. The thicker lines indicate the existence of higher strength in the 
‘communications’ between the network nodes. Middle row and bottom row. A variable 
degree of inter-connectedness between the nodes is shown. The node in red is the 
reference node in the examples of high or low levels of connectivity. 
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4.2. Main hypotheses 
This study tested two hypotheses: 
 
1) Brain regions that are more densely interconnected accrue more tau 
pathology. 
 
2) In Alzheimer’s disease, where tau accumulation is predominantly 
cortical, the functional consequence is that affected nodes become more 
weakly connected and local efficiency of information transfer is reduced. 
 
To test these hypotheses, we assessed, in patients with AD pathology 
(clinically probable AD patients and MCI amyloid positive patients, MCI+), 
relative to controls, the role of in vivo tau burden, as assessed by the PET 
ligand [18F] AV-1451, in mediating graph measures of rsfMRI data.  
 
4.3. Participants  
Fifteen patients with AD pathology, including patients with clinical diagnosis 
of probable AD according to consensus criteria (n=9) (McKhann et al. 
2011b), and MCI with positive amyloid PET scan (n=6) (MCI+) were 
included (Okello et al. 2009d). We also recruited 12 age- and gender-
matched healthy controls.  
 
Both groups overlapped with the participants described in the previous 
chapter with the exception of one control participant who was excluded in 
the present study due to poor quality of his rsfMRI data (excessive head 
movement, i.e., >3mm). 
 
4.4. rsfMRI data acquisition and pre-processing 
rsfMRI multi-echo data were obtained for 10 minutes. Pre-processing 
employed the ME-ICA pipeline (Kundu et al. 2012a, 2013b), which uses 
independent component analysis to classify BOLD and non-BOLD signals 
based on the identification of echo time (TE) dependent components. This 
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provides an optimal approach to correct for movement-related and non-
neuronal signals, and is therefore particularly well suited to this study, in 
which systematic differences in head movement might have reasonably 
been expected in the AD/MCI+ group. 
 
The Harvard-Oxford atlas was sub-parcellated into 598 regions of equal 
volume. rsfMRI images were co-registered to a T1-weighted image from the 
same session and then warped to the template space by the flow fields 
generated from a study-specific anatomical template created using DARTEL 
(Ashburner 2007). The whole-brain was parcellated into nodes of equal size 
(separately for patients and controls), therefore the graph metrices 
calculated at each node represented the connectivity at that node 
independently of the volume. 
The BOLD time series for each node was extracted using the CONN 
functional connectivity toolbox (Whitfield-Gabrieli & Nieto-Castanon 2012). 
Between-node association matrices were generated, and then z-
transformed for further analysis. 
 
4.5. rsfMRI connectivity analyses 
Graph theoretical analysis was used to investigate the global and local 
characteristics of brain networks. These metrics were calculated in python 
using the Maybrain software (github.com/rittman/maybrain) and networkx 
(version 1.11). Here we examined network thresholds from 1 < x < 10%, 
representing a range of graphs from sparse to dense (Alexander-Bloch et 
al. 2010). Very sparse graphs contain less information and can miss 
important relationships. Conversely, very dense graphs are more subject to 
noise and, when binarized, begin to provide less meaningful information. 
Therefore, in what follows, we present the primary statistical analyses at an 
intermediate density of 6%, with statistical detail given for this density.  
Weighted degree was analysed in its raw form, and all other metrics 
were dissociated from variation in degree by binarisation after thresholding 
and normalisation against 1,000 random graphs with the same number of 
connections at each node. 
 78 
4.6. Statistical analyses 
All statistical analyses were performed in Matlab 2015b. The primary 
between-subject analysis was undertaken across the whole-brain. For each 
individual, we first calculated a measure of disease-related tau burden. For 
patients with AD, in whom tau deposition increases in both magnitude and 
distribution as disease progresses (Braak & Braak 1995), tau pathology was 
calculated as average [18F] AV-1451 binding across the whole-brain,. This 
measure of subject-specific tau burden was then correlated with whole-
brain averaged graph metrics to assess the relationship between the metric 
in question and disease burden in each group separately.  
 
The region-specific tau burden per subject was correlated with the graph 
metric values at each node and next the gradient of the best fit linear 
regression within each group was the outcome measure. The data in the 
superior cerebellar region were not included (as this was the reference 
region for PET imaging), while the remaining regional maps were collapsed 
into a vector. This was correlated with a matching vector of local tau burden 
at each node, calculated as the group-averaged increase in [18F] AV-1451 
binding potential (the group average refers to the average within each 
group, i.e., AD/MCI+ and controls, separately).   
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4.7. Results 
4.7.1. More Tau pathology in densely connected nodes 
As we parcellated the brain into nodes of equal size, the weighted degree 
is a measure of the volume of cortex to which a node is connected, and the 
strength of these connections. In other words, the calculation of the 
weighted degree took into account the volumetric differences between 
patients and controls at each node.  
In AD/MCI+ patients, the more strongly connected nodes had higher 
18F-AV-1451 binding (Pearson’s r = 0.48, P < 0.0001, Spearman’s rho = 
0.48, P < 0.0001) (Figure 12 left). This was also true when examining the 
data for the clinically probable AD and MCI+ patients, separately (AD, 
Pearson’s r = 0.34, P <0.001, MCI+ Spearman’s rho = 0.28, P<0.01). This 
relationship was also observed within patients, although their early disease 
stage did not enable further analyses of the impact of the Braak’s stage on 
the main findings. 
In contrast, controls did not show a relationship between the weighted 
degree and 18F-AV-1451 binding (Pearson’s r = 0.03, Spearman’s rho = 
0.11) (Figure 12 right). Finally, all these findings were confirmed at all 
examined network density thresholds.  
 
Figure 12: Relationship between tau pathology and weighted degree. 
Connection strength (weighted degree) at each node plotted against 18F-AV-1451 binding 
potential at that node. A statistically significant linear relationship is only found in 
Alzheimer’s disease but not controls. 
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4.7.2. Reduced cortical connectivity strength in AD 
To assess the impact of the presence of tau on connection strength, we first 
averaged weighted degree across the whole brain, resulting in a single 
measure for each individual. As the overall number of connections in each 
individual graph was thresholded at an identical network density, this 
measure represented the average strength of the strongest X% of 
connections. 
 
To assess global disease burden in AD, we averaged [18F] AV-1451 binding 
values across the whole-brain. In AD patients, a negative correlation 
between average connection strength and global tau burden was found (r=-
0.58, p=0.015).  We hypothesised that this effect would be greatest in 
those regions that display the strongest functional connectivity in the 
healthy brain, and which we have demonstrated to accrue most tau in AD. 
We assessed this by repeating the correlation of global disease burden 
against weighted degree at every individual node. The gradient of this node-
wise relationship reflects a measure of local change in weighted degree with 





Figure 13: Relationship between tau pathology and local connectomic indices. 
 (A) Average 18F-AV-1451 binding potential at each node in Alzheimer’s disease (AD) 
patients and controls. (B-F) The local tau burden-related change in terms of connectomic 
metrics is plotted for each group at each node. Red spheres represent local increases as a 
result of greater overall tau burden; blue spheres represent local decreases.  
 
Firstly, we examined whether the whole-brain average relationship could be 
replicated in these individual gradients, by performing sign tests. For AD, a 
negative relationship was confirmed (Z=-13.0, P< 0.0001); while for 
controls no relationship was demonstrated using either whole brain (Z=-
1.1, P=0.27) or deep brain (Z=1.1, P=0.27) tau burden.  
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Next, we assessed whether the functional connectivity change at each node 
related to local tau burden, by correlating the gradient of the disease-
related change with the disease-associated increase in [18F] AV-1451 
binding potential at each node (Figure 13). A negative correlation between 
these measures was demonstrated in AD (r=-0.30, P< 0.0001) but not 
controls (r=-0.01, P=0.75). Finally, we assessed whether the functional 
connectivity change at each node related to the strength of its connections 
in the healthy control brain. As would be expected from the propensity of 
highly connected nodes to accrue tau, a negative relationship was 
demonstrated in AD (r =-0.23, P< 0.0001). Importantly, however, this 
relationship explained less variance than AV binding, with which we have 
demonstrated it to be correlated.  
 
In summary, nodes that are constitutionally more strongly connected, such 
as those in parietal and occipital lobes, are more likely to accrue tau 
pathology in AD patients. Once present, the tau pathology causes local 
functional connectivity strength to fall.  
 
4.7.3. Local connectivity reorganization relates to local tau 
pathology in AD 
As illustrated in Figure 14, the reorganisation of graph metrics followed 
two distinct patterns.  
 
Closeness centrality displayed a global effect, with most nodes increasing 
in AD. This was not related to local [18F] AV-1451 binding potential in AD 
(r= 0.05, P=0.25).  
 
By contrast, eigen-centrality was more strongly related to local [18F] AV-
1451 binding in AD (r=-0.28, P<0.0001). Strikingly, the positive 
relationship we demonstrated across the whole brain masked opposing 
regional effects. As global tau burden increased, the functional influence of 
frontal regions on all other regions increased, while that of occipital regions 
decreased.  
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Both local efficiency and betweenness centrality displayed an intermediate 
degree of regional specificity in AD, being moderately correlated with 
change in [18F] AV-1451 binding in AD (local efficiency r=-0.16, P<0.0001, 





































We have demonstrated that in Alzheimer’s disease a relationship exists 
between the propensity of a node to display elevated 18F-AV-1451 binding 
and the volume of cortex to which it is connected.  
 
Furthermore, we have explored the consequences of tau accumulation with 
cross-sectional analyses at a variety of spatial scales. In Alzheimer’s 
disease, we have demonstrated that with greater levels of tau pathology 
the strongest internodal connections are weakened. This reorganization of 
the brain network leads to more direct long-range connections passing 
through fewer nodes, at the cost of lower local efficiency. 
 
It has been proposed that the pathological mechanisms underlying AD begin 
in a single, vulnerable location and spread from cell to cell, rather than 
occurring independently in a large number of vulnerable cell populations 
(Guo and Lee, 2014; Goedert, 2015). The primary direct evidence for such 
propagation of tau comes from rodent studies. For example, the injection 
of brain extract from transgenic mice expressing mutant tau into mice 
expressing wild-type human tau caused wild-type tau to form filaments and 
spread to neighbouring brain regions (Clavaguera et al., 2009).  
 
Furthermore, pathological tau from human brains causes disease in wild-
type mice, in which the pathological human tau species becomes self-
propagating (Clavaguera et al., 2013). This tau propagation is mediated by 
the presence and strength of synaptic connectivity rather than spatial 
proximity (Liu et al., 2012; Iba et al., 2013; Ahmed et al., 2014). 
Associative studies of the healthy brain have demonstrated that large-scale, 
functionally connected neural networks strongly resemble the known 
patterns of atrophy in distinct neurodegenerative syndromes (Zhou et al., 
2012).  
 
Here, we go beyond these studies to measure tau burden and functional 
connectivity in the same individuals at both the whole-brain and regional 
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level. We observe that those brain areas that are more functionally 
connected show more tau pathology in Alzheimer’s disease. We 
demonstrate that the presence of tau is not, in itself, inducing stronger 
regional connectivity by our cross-sectional analysis of the Alzheimer’s 
disease group, in which we demonstrate that higher cortical tau relates to 
overall lower functional connectivity.  
 
Crucially, we demonstrate that 18F-AV-1451 binding potential at each node 
is better than the connectivity of that node in the healthy brain at 
accounting for regional variance in connectivity change, arguing against the 
presence of tau being a secondary marker of neurodegeneration in 
vulnerable hubs. In other words, it is not coincidence that Alzheimer’s 
disease tends to impact large networks; it is a predictable consequence of 
trans-neuronal spread of a disease-causing protein. Graph theoretic models 
of transmissible disease epidemics are in agreement that the likelihood of 
an individual becoming infected (and the dose of the infectious agent 
received) is directly proportional to its number of infected neighbours and 
their infectivity (Durrett, 2010).  
 
As our nodes represent brain regions of equal volume, the binary portion of 
degree represents a surrogate measure of the number of neurons to which 
a brain region is connected, and the weighted portion of degree is a 
measure of the strength of these connections. By the time Alzheimer’s 
disease is sufficiently advanced to cause symptoms, tau is generally already 
present to some degree throughout the neocortex (Markesbery, 2010), and 
therefore reaching a disease stage at which the number of neighbours more 
closely approximates the number of infected neighbours, and the 
connection strength between infected neighbours (here the weighted 
portion of degree) becomes a strong driver of infectivity. 
 
Conversely, our analyses do not provide support for models of hub 
vulnerability in Alzheimer’s disease. It is important to acknowledge that this 
does not mean that these mechanisms are unimportant, but rather that 
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they may be a downstream event of tau accumulation. In other words, while 
we demonstrate that the propensity of a node to accrue tau is not related 
to trophic support, these factors might still contribute to determining the 
vulnerability of brain regions to the presence of a given amount of tau. This 
hypothesis could be addressed in future studies by relating the information 
content of tau ligand binding to other measures of neurodegeneration such 
as longitudinal changes in grey matter volume. 
 
There are a series of limitations of our study. First, our analysis was cross-
sectional, and we used 18F-AV-1451 binding as a surrogate marker of tau 
burden. By making observations about the relationship between tau burden 
and functional connectivity in this way, we assume a uniformity of effect 
within our disease groups. Longitudinal assessment of tau burden and 
functional connectivity in the same individuals will be an important and 
powerful validation of our results. Evidence of the causal relationship 
between tau and connectivity will also require interventional studies 
targeting tau pathology.  
 
Second, it should also be noted that 18F-AV-1451 binding identifies 
predominantly aggregated tau in tangles, and does not directly measure 
oligomeric tau, nor extracellular forms of tau that may mediate spread of 
pathology and which may be more toxic to the cell and synaptic plasticity.  
 
Third, our analysis is focused towards cortico-cortical functional 
connectivity. In particular, multi-echo MRI might have a poor signal-to-
noise ratio in deep brain structures, although the main advantage of using 
this sequence is that it enables robust de-noising of movement-related 
artefacts pipeline (Kundu et al., 2012, 2013). This is critical in clinical 
populations, in which functional MRI data may differentially suffer from 
quality degradation due to head movements. 
 
Fourth, by examining proportionately thresholded graphs with 1–10% 
density, our analysis focusses on the strongest interregional functional 
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connections. However, it is possible that we are missing additional effects 
of neurodegeneration on weak or medium-strength connections. Tract-
tracing studies indicate that there are weak anatomical connections, 
equivalent to a few axons, between some cortical areas (Ypma and 
Bullmore, 2016). Such weak links may have functional importance in 
complex networks (Granovetter, 1983). However, weak connections are 
difficult to evaluate with functional MRI, as it is not possible to disentangle 
them from correlation arising from signal noise. Future evaluation of these 
weaker connections with in vivo tractography, neuropathology or novel 
methods might reveal additional effects not evident in our dataset.  
 
In the interim, the thresholding procedure retains several advantages; by 
retaining only the most strongly correlated edges one is less likely to include 
false positive correlations and topologically random edges. It also allows the 
computationally intense process of normalization of metrics against random 
graphs of equal density. The consistency between the results using 
thresholded nodal weighted degree and unthresholded nodal connectivity 
strength provides reassurance in the choice of thresholding of connections. 
 
To conclude, this study reveals the relationship between tau burden and 
functional connectivity in AD. Our results have wide-ranging implications, 
from the corroboration of models of tau trafficking in humans to validating 
computational models of hub compensation in Alzheimer’s disease. These 
insights into the relationship between tau burden and brain connectivity 




Chapter 5| [11C]PK11195 PET to assess 




In this Chapter, I present part of the findings of my recently published 
study, in which I assess in vivo neuroinflammation in AD via PET imaging 
(Passamonti et al. 2018).  
 
Neuro-inflammation is a common feature in the pathogenesis of AD and 
other neurodegenerative disorders. Animal and human studies have indeed 
provided converging evidence that microglia, the brain’s principal innate 
immune system, show increased activation in AD, Parkinson’s disease (PD), 
Huntington’s disease (HD), and other neurodegenerative disorders 
(Fernandez-Botran et al. 2011b; Edison et al. 2013b; Schuitemaker et al. 
2013b; Fan et al. 2015b; Stefaniak & O’Brien 2016b).  
 
For example, the release of cytokines like interleukin-1ß and TNF-ß, 
mediated by the microglia, can accelerate neurodegeneration and synaptic 
loss in AD (Fernandez-Botran et al. 2011b), while microglia can also 
promote phagocytosis and clearance of amyloid plaques (Wisniewski et al. 
1991).  
 
In addition, genetic associations studies in different neurodegenerative 
disorders reveal variations in genes that contribute to immune signalling 
and response (Villegas-Llerena et al. 2016). For example, variations in 
genes such as SORL1 (sortilin-related receptor) and TREM2 (triggering 
receptor expressed on myeloid cells 2) that have been involved in 
inflammation and immune responses have been suggested as risk factors 
of late onset AD on the basis of a genome-wide association studies 
(GWAS) (Villegas-Llerena et al. 2016).  
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This raises the possibility of immune-therapeutic strategies for prevention 
and disease modification.  
 
However, key issues remain to be addressed before such strategies could 
be employed, including the confirmation of clinico-pathological correlations 
of inflammation and the potential utility of imaging biomarkers for 
measuring and tracking inflammation in the central nervous system. 
Despite the importance of neuro-inflammation in AD, there is still 
insufficient information regarding the extent and regional distribution of 
microglia-activation in patients with AD, and the clinical correlates of 
inflammatory biomarkers.  
 
Inflammation in the central nervous system can be measured indirectly, 
using positron emission tomography (PET) in conjunction with radio-ligands 
like [11C]PK11195 which bind to the mitochondrial translocator protein 
(TSPO) in activated microglia. Ligands such as [11C]PK11195 are well 
established biomarkers of neuro-inflammation, although one must bear in 
mind that microglial activation represents only part of the complex cascade 
of events in neuro-inflammation (Agostinho et al. 2010). Relative to 
controls, [11C]PK11195 PET has been shown to be abnormal in AD, PD, 
Huntington’s disease (Cagnin et al. 2001a; Gerhard et al. 2006a, 2006b; 
Anderson et al. 2007; Edison et al. 2013a); although results across studies 
were mixed  (Kropholler et al. 2007; Wiley et al. 2009).  
 
Differences in the magnitude and regional distribution of microglial 
activation also need to be related to the cognitive deficit. In this study, I 
used the [11C]PK11195 tracer, a well-established PET marker of in vivo 
microglial activation (Agostinho et al. 2010) to assess the magnitude and 
patterns of [11C]PK11195 binding in patients with AD and MCI (with positive 
amyloid PET PiB scan) in comparison to age- and education-matched 
healthy controls. I also assessed whether the [11C]PK11195 binding in 
different brain regions related to cognitive deficit in AD.  
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5.2. Main aim and hypotheses 
The main aim of the study described in this chapter were to test the 
following hypotheses:  
 
1) that patients with AD and MCI+ show increased microglia activation in 
cortical and sub-cortical areas typically associated with AD pathology, 
including the medial temporal lobe as well as parietal and lateral temporal 
cortices (Serrano-Pozo et al. 2011). 
 
2) that higher microglia activation in brain regions which are characteristic 




The same group of AD and MCI+ patients previously described in chapter 3 
and chapter 4 was included in this study.  
 
However, a different group of thirteen age-, education-, and sex-matched 
healthy controls with no history of major psychiatric or neurological 
illnesses, head injury or any other significant medical co-morbidity (in 
particular, systemic inflammatory or auto-immune disorders disorders) was 
included here to allow group-wise comparisons with the AD cohort. 
 
The control participants included in this study were different from those 
described in chapter 3 and 4 due to ethical reasons that limited the amount 
of PET-related radiation in healthy participants. 
 
Details of participant demographics and cognitive features are provided in 
Table 5. Table 6 also shows that there are no demographic or clinical 




Table 5: Participants’ demographic and clinical details (microglia PET study). 
Participant details (mean, with standard deviation (SD) and range in parentheses) and group 
differences by chi-squared test or one-way analysis of variance. AD/MCI+: Alzheimer’s disease/mild 
cognitive impairment (amyloid positive on Pittsburgh Compound-B positron emission tomography 
scan); MMSE: Mini Mental State Examination; ACE-R: Addenbrooke’s Cognitive Examination Revised, 




Table 6: Clinical details in AD, MCI+, and controls (microglia PET study). 
Participant details (mean, with standard deviation (SD) and range in parentheses) and group 
differences by chi-squared test or one-way analysis of variance. AD/MCI+: Alzheimer’s disease/mild 
cognitive impairment (amyloid positive on Pittsburgh Compound-B positron emission tomography 
scan); MMSE: Mini Mental State Examination; ACE-R: Addenbrooke’s Cognitive Examination Revised, 
RAVLT: Rey Auditory-Verbal Learning Test (delayed recall, 30 minutes). NS, not significant at P<0.05 
(uncorrected). 
Demographic & Clinical 
data 
AD / MCI+ (n=15) Controls (n=13) Group 
difference 
Sex (males/females) 9/6 5/8 N/S 
Age (years) (SD, range) 71.6 (±8.7, 54-85) 68.0 (±5.3, 59-81) NS 
Education (years) (SD, 
range) 
13.8 (±3.1, 10-19) 14.1 (±2.7, 10-19) NS 
MMSE (SD, range) 25.5 (±2.8, 18-28) 28.7 (±1.0, 27-30) F=7.60, 
P=0.002 
ACE-R (SD, range) 75.9 (±11.0, 51-
89) 
91.3 (±5.3, 79-99) F=7.58, 
P=0.002 









Sex (males/females) 2/7 4/2 5/8 N/S 




72.2 (±9.7, 58-83) 68.0 (±5.3, 59-81) NS 




13.0 (±2.9, 10-18) 14.1 (±2.7, 10-19) NS 
MMSE (SD, range) 25.1 (±3.4, 18-
28) 
26.2 (±1.1, 25-28) 28.7 (±1.0, 27-30) F=6.43, 
P=0.04 
ACE-R (SD, range) 72.9 (±11.7, 51-
89) 
80.3 (±8.0, 66-87) 91.3 (±5.3, 79-99) F=4.9, 
P=0.02 
RAVLT (SD, range) 0.9 (±1.3, 0-4) 1.2 (±1.2, 0-3) 9.7 (±3.2, 3-15) F=11.3, 
P<0.0001 
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5.4. PET protocol 
[11C]PK11195 was produced with high radiochemical purity (>95%). 
[11C]PK11195 specific activity was around 85 GBq/μmol at end of syntesis. 
The emission protocol was 75 minutes of dynamic imaging (55 frames) 
starting concurrently with a 500 MBq [11C]PK11195 injection. 
 
Each emission frame was reconstructed using the PROMIS 3-dimensional 
filtered back projection algorithm into a 128x128 matrix 30cm trans-axial 
field of view, with a trans-axial Hann filter cut-off at the Nyquist 
frequency(Kinahan & Rogers 1989b). Corrections were applied for randoms, 
dead time, normalization, scatter, attenuation, and sensitivity. Each 
emission image series was aligned using SPM8 to reduce the effect of 
patient motion during data acquisition. 
 
The mean aligned PET image (and hence the corresponding aligned PET 
image series) was rigidly registered to the T1-weighted MR image. For 
[11C]PK11195, supervised cluster analysis was used to determine the 
reference tissue time-activity curve (Turkheimer et al. 2007). All ROI data 
were corrected for CSF contamination through division with the mean ROI 
probability (normalized to 1) of grey + white matter, using SPM8 probability 
maps smoothed to PET resolution. To test whether correction for CSF 
affected the main results, I repeated all the [11C]PK11195 ROI PET analyses 
using data not corrected for CSF contamination.  
 
To compare [11C]PK11195 binding across groups (AD/MCI+ and controls), 
individual ROI binding values for [11C]PK11195 were used in a repeated-
measures general linear model (GLM) to test for the main effect of ROI, 
main effect of group, and group × ROI interaction. Age and sex were 
included as covariates of no interest. For the AD/MCI+ group, we also 
tested Pearson’s correlations between regional [11C]PK11195 BPND and 
cognitive impairment using the RAVLT scores. All analyses were repeated 
using [11C]PK11195 BPND values that were not corrected for CSF partial 
volume effects. 
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5.5. PET findings 
The mean [11C]PK11195 BPND voxel-wise maps (Figure 15) and ROI 
analyses (Figure 16), indicated that in both groups (including controls), 
the highest binding of [11C]PK11195 was localized to the thalamus, basal 
ganglia, and brainstem.  
 
In the repeated-measures GLM of regional binding, we found a significant 
main effect of ROI (F2,36=3.8, P<0.001), main effect of group (F2,36=5.7, 
P<0.006), and a group × ROI interaction (F2,70=2.6, P<0.001). The group 
and interaction effects were driven by higher [11C]PK11195 binding in the 
AD/MCI+ relative to the control group, in the occipital, parietal, and 
temporal cortices, as well as in the hippocampus, amygdala, and other 
medial temporal lobe ROIs (post-hoc t-tests, T’s>2.0, P’s<0.05). 
 
Figure 15: [11C]PK11195 findings in AD/MCI+ and controls (voxel-wise data). 
Mean [11C]PK11195 PET map in each group. Patients with AD pathology (including clinically 
probable AD and MCI+ patients) showed increased [11C]PK11195 binding in medial 
temporal lobe regions and other cortical areas, relative to controls. 
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Figure 16: [11C]PK11195 findings in AD/MCI+ and controls (ROI analyses). 
Mean (± standard error) [11C]PK11195 non-displaceable binding potential (BPND) in each 
region of interest for the participant groups: Alzheimer’s disease (AD) and amyloid positive 
mild cognitive impairment (MCI+); healthy controls (HC). The [11C]PK11195 BPND data 
reported here are corrected for cerebro-spinal fluid (CSF) contamination.  
 
 
Next, I examined the [11C]PK11195 ROI binding in AD and MCI+ groups 
separately, relative to controls, with the caveat of the small sample size in 
each group of patients (AD=9, MCI+=6). Nevertheless, there were still 
group and interaction effects that were driven by higher [11C]PK11195 
binding in the patients’ groups relative to controls (F=3.8, P<0.01), 
although the difference between AD and MCI+ patients were overall not 













Figure 17: [11C]PK11195 findings in AD, MCI+, and controls (ROI analyses). 
Mean (± standard error) [11C]PK11195 non-displaceable binding potential (BPND) in each 
region of interest for the participant groups: clinically probable Alzheimer’s disease (AD), 
amyloid positive mild cognitive impairment (MCI+) (red bars); healthy controls (HC) 
(green bars). The [11C]PK11195 BPND data reported here are corrected for cerebro-spinal 
fluid (CSF) contamination.  
 
Repeating these analyses using the ROI [11C]PK11195 binding values that 
were not corrected for CSF partial volume effects yielded similar results 
(F=2.2, P<0.0001, for the main effect of ROIs; F=6.1, P<0.006 for the main 
effect of group; and F=2.0, P<0.0001 for the group × ROI interaction). This 
additional analysis demonstrate that our main findings were robust against 
between-groups effects that might have been driven by differences in grey-
matter atrophy between patients and controls. 
 
We then tested whether regional [11C]PK11195 binding related to memory 
deficits in patients with AD/MCI+. In this group, there was a significant 
negative correlation between the RAVLT scores (delayed recall at 30 
minutes) and [11C]PK11195 binding in the cuneus / pre-cuneus (r=0.50, 
P<0.05). Repeating the correlation analyses when using the ROI 
[11C]PK11195 binding values that were not corrected for CSF volume made 
the result in the AD/MCI+ group not-significant (R=0.31, P=0.2). 
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5.6. Discussion 
This study demonstrates that AD, in the form of clinically probable AD and 
MCI with biomarker evidence of AD pathology is associated with 
significantly increased in vivo microglia activation, as indexed by the 
[11C]PK11195 ligand.  
 
The brain regions with the most marked abnormalities of [11C]PK11195 
binding in AD/MCI+ were those predicted from the established distribution 
of neurodegeneration in AD. Specifically, patients showed increased 
inflammation in the medial temporal lobe as well as parietal and lateral 
temporal cortices relative to controls (Braak & Braak 1995; Braak et al. 
2006a; Ossenkoppele et al. 2016b; Scholl et al. 2016b; Schwarz et al. 
2016c).  
 
Together, these data demonstrate that the density and distribution of 
activated microglia in living patients with AD mirror the typical pathological 
changes characteristic of this disorder. This could result from a causal link 
between neuroinflammation and neurodegeneration, although the 
association might also derive from the process of neurodegeneration itself. 
 
A cross-sectional and non-interventional study such as this one cannot 
alone provide the direction of causality. Nevertheless, the disease-specific 
anatomical distributions of activated microglia in AD suggest a regional 
association rather than a side effect of a global increased [11C]PK11195 
binding in response to a systemic inflammatory insult.  
 
Our PET data are also in keeping with post mortem findings, which 
demonstrated that microglia burden (as assessed via LN3-immuno-
staining) and cytokine expression (i.e., IL-1ß and TGF-ß expression) show 
a disease-specific topological relationship with the pathological hallmarks of 




More specifically, AD patients have significantly higher microglia density and 
IL-1ß expression in the parietal and other posterior cortices when compared 
to controls. The expression of TGF-ß is also increased in the same cortices 
in AD patients, relative to controls. Overall, this suggests that microglia 
activation and cytokine expression co-exist with the pathogenic processes 
underlying AD and could contribute to the on-going neurodegeneration. If 
this is the case, this would warrant the further investigation of immune-
therapeutic strategies to modulate neuro-inflammation in AD, although 
evidence from earlier anti-inflammatory trials in AD remains controversial 
(Adapt Research Group et al. 2007, 2008). 
 
My data also confirmed the hypothesis that [11C]PK11195 binding correlates 
with episodic memory impairment as assessed via the RAVLT in patients 
with AD/MCI+, although these findings were only evident when the date 
were corrected for partial volume (which may reflect an effect of local grey-
matter atrophy). Nevertheless, as for the main effect of group, this effect 
was not a global correlation, but adhered to the functional anatomy of 
typical cognitive symptoms in the amnestic form of AD and MCI with 
amyloid pathology.  
 
Technical aspects of the PET methods need consideration. In particular, the 
supervised cluster method for estimating [11C]PK11195 BPND could have 
introduced an under-estimation bias, as the reference tissue may have still 
included specific binding of the radio-ligand. If present, this would be likely 
to have reduced the effect sizes (increased type II error) rather than 
increasing type I error.  
 
I also highlight that my data are specific to [11C]PK11195 and do not 
inevitably generalize to second-generation ligands (e.g., PBR28) or 
alternative tracers of neuroinflammation over and above those that bind to 
the mitochondrial translocator protein (TSPO) (e.g., COX-1, MPO, 
macrophage infiltration) (Suridjan et al. 2015; Hamelin et al. 2016; 
Yokokura et al. 2016).  
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Further studies could assess the utility of such novel markers for in vivo 
imaging of neuroinflammation, bearing in mind that the binding of second-
generation TSPO tracers such as PBR28 may be affected by genetic 
variations (i.e., the rs6971 polymorphism in the TSPO gene)(Owen et al. 
2012). 
 
In conclusion, my data provided evidence that [11C]PK11195 is a sensitive 
PET ligand for in vivo studies of microglia activation in AD and its prodromal 
stage of MCI. This supports the further use of [11C]PK11195 PET to assess 
microglia activation in neurodegenerative disorders and in clinical trials that 
aim to modulate neuroinflammation in AD. 
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Chapter 6| Microglia activation and 
network dysfunction in Alzheimer’s 
disease 
 
6.1. Introduction  
In this chapter, I examine the impact of in vivo neuroinflammation 
(described in Chapter 5) on brain-wide network function in AD. I also study 
how this functionally-relevant neuroinflammation is linked to cognitive 
deficit in AD.  I undertake a multi-modal and multivariate imaging approach 
to combine [11C]PK11195 quantification of regional neuroinflammation with 
resting-state functional imaging (rsfMRI) in patients at different stages of 
AD. Patients with AD and MCI+ were compared to age-, sex-, and 
education-matched healthy controls in terms of neuroinflammatory 
patterns, rsfMRI connectivity, and their relationship in mediating cognitive 
deficit.  
 
Neuroinflammation plays a key role in the etio-pathogenesis of Alzheimer’s 
disease and other neurodegenerative disorders (Edison et al. 2008a; 
Fernandez-Botran et al. 2011b; Fan et al. 2015b; Stefaniak & O’Brien 
2016b). Pre-clinical models (Heppner et al. 2015; Hoeijmakers et al. 2016; 
Villegas-Llerena et al. 2016; Li et al. 2018; Wang et al. 2018), and research 
in humans (Edison et al. 2008a; Fernandez-Botran et al. 2011b; Fan et al. 
2015b; Stefaniak & O’Brien 2016b), demonstrate that the microglia, part of 
the brain’s innate immune system, are activated in Alzheimer’s and related 
diseases.  
 
Although the mechanisms and mediators of inflammatory risk in Alzheimer’s 
disease are not fully understood, synaptic and neuronal injury may arise 
from the release of cytokines and pro-inflammatory molecules such as 
interleukin-1ß and TGF-ß (Fernandez-Botran et al. 2011b), or direct 
microglial injury to synapses (Hong et al. 2016; Hong & Stevens 2016).  
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These, in turn, impair synaptic function, network communication, and may 
accelerate neurodegeneration and synaptic loss (Heppner et al. 2015; 
Hoeijmakers et al. 2016; Villegas-Llerena et al. 2016; Li et al. 2018; Wang 
et al. 2018). In addition, genetic association studies have demonstrated a 
link between Alzheimer’s disease and polymorphisms and mutations of 
genes linked to immune responses (Villegas-Llerena et al. 2016).  
 
Clinical studies of neuroinflammation in dementia have exploited positron 
emission tomography (PET) ligands that bind to the mitochondrial 
translocator protein (TSPO) in activated microglia (Cagnin et al. 2001b; 
Gerhard et al. 2004, 2006a; Edison et al. 2013a, 2013a; Fan et al. 
2015c)[1, 2, 10, 13-17]. As shown in Chapter 5, patients with Alzheimer’s 
disease, relative to controls, have higher [11C]PK11195 binding in the 
hippocampus, other medial-temporal lobe regions, and posterior cortices 
such as the pre-cuneus, which in turn correlates with cognitive deficit 
(Passamonti et al. 2018).  
 
A critical and unanswered question is whether regional neuroinflammation 
changes the functional connectivity of large-scale networks. Such large-
scale neural networks represent an intermediate phenotypic expression of 
pathology in many diseases, that can be non-invasively quantified with 
resting-state functional magnetic resonance imaging. A challenge is that 
neither the anatomical substrates of cognition nor the targets of 
neurodegenerative disease are mediated by single brain regions: they are 
in contrast distributed across multi-variate and interactive networks. In 
other words, neuroinflammation in AD is distributed across multiple brain 
networks, and the impact of AD may be seen through changes in multiple 
modalities of neural and cognitive functions. This multivariate nature of 
neuroinflammatory and cognitive mechanisms in AD calls for a different 
statistical approach to that used so far.  
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We therefore undertook a multimodal and multi-variate statistical approach 
to combine [11C]PK11195 quantification of distributed neuroinflammation 
with resting-state functional imaging in patients at different stages of 
Alzheimer’s disease (i.e., clinically probable AD and MCI with evidence of 
amyloid pathology).  
 
The set of PET, rsfMRI, and cognitive data was complex, and our sample 
size was relatively small. Therefore, to reduce the dimensionality (i.e., 
complexity) of data we used the novel “source-based inflammetry” (SBI, 
directly analogous to ‘source-based morphometry’ of brain volumes). SBI 
is a statistical procedure that decomposes the PET images across all 
individuals in a set of spatially independent sources (Xu et al. 2009). This 
way it is possible to compute a spatially distributed (i.e., voxel-wise) single 
measure of microglia activation in each individual. This index can be next 
employed as a regressor term in second level analyses including functional 
connectivity patterns in the whole-brain as the main outcome measure.  
 
SBI was augmented by multiple linear regression models that associated 
neuroinflammation, functional network connectivity in distinct components, 
and cognition. 
 
6.2. Main hypotheses  
I tested two hypotheses:  
 
1) that microglia activation is associated with significant changes in large-
scale functional connectivity in patients with AD, relative to controls;  
 
2) that the relationship between microglia activation and functional 





6.3. Participants & Methods 
In the analyses reported in this Chapter, I included 14 patients meeting 
clinical diagnostic criteria for probable AD (McKhann et al. 2011b), and 14 
patients with MCI and biomarker evidence of amyloid pathology (positive 
Pittsburgh Compound-B PET scan) (MCI+) (Okello et al. 2009d).  
Therefore, relative to the patients described in Chapter 3 and 5, an 
extra n=5 AD and n=8 MCI+ patients were included in this Chapter due to 
an additional recruitment wave that intercurred across the studies.  One 
further control was also enrolled since the experiments described in Chapter 
3 and 5 leading to a total of fourteen age-, sex-, and education-matched 
healthy controls. A new table (Table 7) of demographic and clinical data is 
thus provided for comparison with Table 4 and 6. 
 
 
Table 7: Demographic and clinical data. 
Participant details (mean, with standard deviation (SD) and range in parentheses) and 
group differences by chi-squared test, one-way analysis of variance or independent 
samples t-test. AD/MCI+: Alzheimer’s disease/mild cognitive impairment (amyloid 
positive on Pittsburgh Compound-B positron emission tomography scan); MMSE: Mini 
Mental State Examination; ACE-R: Addenbrooke’s Cognitive Examination Revised, 
RAVLT: Rey Auditory-Verbal Learning Test (delayed recall). NS, not significant with 
p>0.05 (uncorrected). 
 
Demographic &  
Clinical data 
AD/MCI+ (N=28) Controls (N=14) Group 
differences 
Sex (females/males) 12/16 8/6 NS 
Age (years) (SD, range) 72.7 (±8.5, 53-86) 68.3 (±5.4, 59-81) NS 
Education (years) (SD, 
range) 
12.9 (±3.0, 10-19) 14.1 (±2.7, 10-19) NS 
MMSE (SD, range) 25.6 (±2.2, 21-30) 28.8 (±1.0, 27-30) T=4.9, P<0.0001 
ACE-R (SD, range) 78.9 (±7.7, 62-91) 91.6 (±5.3, 79-99) T=5.5, P<0.0001 
RAVLT (SD, range) 1.5 (±1.6, 0-6) 9.6 (±3.2, 3-15) T=10.8, P<0.0001 
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6.3.1. Clinical and cognitive assessment 
Clinical indices of cognitive decline included Mini Mental State Examination 
(MMSE), Addenbrooke’s Cognitive Examination-Revised (ACE-R), and Rey 
auditory verbal learning test (RAVLT).  
 
For a single summary measure across the three cognitive scales, I 
conducted a Principal Component Analysis (PCA) on the ACE-R, MMSE, and 
RAVLT scores to reduce the dimensionality into one latent variable 
(cognitive deficit) which summarizes the largest portion of shared variance 
as the first principal component (COG-PC1).  
 
6.3.2. rsfMRI pipeline 
The location of the key cortical regions in each network was identified by 
spatial independent component analysis (ICA) using the Group ICA of fMRI 
Toolbox (GIFT)(Calhoun et al. 2001b) in an independent dataset of 298 age-
matched healthy individuals from a large population-based cohort in the 
Cambridge Centre for Ageing and Neuroscience (Shafto et al. 2014b). 
Further details about pre-processing and node definition can be found in 
Tsvetanov and colleagues (Tsvetanov et al. 2016b).  
 
Four networks were identified by spatially matching to pre-exsing templates 
(Shirer et al. 2012b). First, the default mode network (DMN), which 
contained six nodes: the ventral anterior cingulate cortex (vACC), the 
middle posterior conjugate cortex (PCC), and the dorsal PCC (dPCC) which 
further divided in the left dPCC and right dPCC), and right and left inferior 
parietal lobes (rIPL and lIPL). Second, the frontoparietal network (FPN) 
which was defined using the left and right superior frontal gyrus (rSFG and 
lSFG) and left and right angular gyrus (rAG and lAG). Third, the cognitive 
network which included the right and left middle frontal gyrus (fMFG, rMFG). 
Forth, the subcortical network that included the bilateral putamen (rPut and 
lPut) and hippocampus (rHipp and lHipp). The node time-series were 
defined as the first principal component resulting from the singular value 
 105 
decomposition of voxels in a 8mm radius sphere, which was centred on the 
peak voxel for each node (Tsvetanov et al. 2016b). After extracting nodal 
time-series we sought to reduce the effects of noise confounds on functional 
connectivity effects of node time-series using a general linear model, GLM. 
This model included linear trends, expansions of realignment parameters, 
as well as average signal in the white-matter (WM) and cerebrospinal (CSF), 
including their derivative and quadratic regressors from the time-courses of 
each node. The WM and CSF signals were created by using the average 
across all voxels with corresponding tissue probability larger than 0.7 in 
associated tissue probability maps available in SPM12 
(http://www.fil.ion.ucl.ac.uk/spm/software/spm12/).  
 
A band-pass filter (0.0078-0.1 Hz) was implemented by including a discrete 
cosine transform set in the GLM, ensuring that nuisance regression and 
filtering were performed simultaneously. The GLM excluded the initial five 
volumes to allow for T1 equilibration. The total head motion for each 
participant, which was used in subsequent between-subject analysis as a 
covariate of no interest, was quantified using the approach reported in 
Jenkinson and colleagues (Jenkinson et al. 2002b), i.e. the root mean 
square of volume-to-volume displacement. As for the analyses reported in 
Chapter 4, we also used independent component analyses that separate the 
changes in the fMRI signal linked to the BOLD response from that associated 
with non-BOLD components (Kundu et al. 2012b, 2013a). This procedure 
has been shown to be particularly robust in de-noising fMRI data from 
several sources of noise including head movement (Kundu et al. 2012b, 
2013a). Finally, the functional connectivity between each pair of nodes was 
computed using Pearson’s correlation on post-processed time-series. 
 
6.3.3. PET acquisition and analysis pipeline 
All participants underwent [11C]PK11195 PET imaging to assess the extent 
and distribution of neuroinflammation while patients with MCI also 
underwent [11C]PiB (Pittsburgh compound-B PET) scanning to evaluate the 
degree of β-amyloid accumulation. [11C]PK11195 and [11C]PiB PET were 
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produced with high radiochemical purity (>95%), with [11C]PiB PET having 
a specific activity >150 GBq/μmol at the end of synthesis, whereas 
[11C]PK11195 specific activity was ∼85 GBq/μmol at the end of synthesis. 
PET scanning used a GE Advance PET scanner (GE Healthcare) and a GE 
Discovery 690 PET/CT, with attenuation correction provided by a 15 min 
68Ge/68Ga transmission scan and a low dose computed tomography scan, 
respectively. The emission protocols were 550 MBq [11C]PiB injection 
followed by imaging from 40 to 70 min postinjection, and 75 min of dynamic 
imaging (55 frames) starting concurrently with a 500 MBq [11C]PK11195 
injection. Each emission frame was reconstructed using the PROMIS 3-
dimensional filtered back projection algorithm into a 128 × 128 matrix 30 
cm trans-axial field-of-view, with a trans-axial Hann filter cutoff at the 
Nyquist frequency (Kinahan and Rogers, 1989). Corrections were applied 
for randoms, dead time, normalization, scatter, attenuation, and sensitivity. 
The [11C]PK11195 maps were co-registered and warped to the 
Montreal Neurological Institute (MNI) space using the flow fields. To 
minimise the noise effects from non-GM regions, the normalised PK maps 
were masked with a group-based GM mask based on voxels having grey-
matter tissue probability larger than 0.3 in GM-segmented images across 
all individuals. The normalised images were smoothed using a 6mm 
Gaussian kernel. We then used independent component analysis (ICA) 
across participants to derive spatial patterns of PK maps across voxels 
expressed by the group in a small number of independent components.  
All PK maps were spatially concatenated and submitted to source-
based ‘inflammetry’ (SBI) to decompose images across all individuals in a 
set of spatially independent sources without providing any information 
about the group, using the GIFT toolbox.  
 
Specifically, the n-by-m matrix of participants-by-voxels was decomposed 
into:  
 
1) a source matrix that maps Independent Components (ICs) to voxels 
(here referred to as PKIC maps),  
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2) a mixing matrix that maps PKICs to participants.  
 
The mixing matrix consists of loading values (1 per participant) indicating 
the degree to which a participant expresses a defined PKIC. The 
independent component loading values for the PKIC were taken forward to 
between-participant analysis of functional connectivity (Figure 18), if they 
were: 
 
(1) differentially expressed by controls vs. patients with AD pathology;  
 
(2) were associated with atrophy (see Results and Figure 19).  
 





Figure 18: Pipeline analyses for the combined PET (microglia) and rsfMRI study. 
Schematic representation of various modality datasets in the study, their processing 
pipelines on a within-subject level (light blue), as well as data-reduction techniques and 
statistical strategy on between-subject level (dark blue) to test for associations between 
the datasets. Abbreviations: PKIC (Independent component [11C]PK11195 maps); FC 
(functional connectivity); Cov. (covariates); COG PC1 (latent variable (cognitive deficit) 
which summarizes the largest portion of shared variance as the first principal component); 
MMSE (Mini Mental State Examination), ACE-R (Addenbrooke’s Cognitive Examination-
Revised); RAVLT (Rey auditory verbal learning test); GM (grey-matter); PiB (Pittsburgh 
Compound-B positron emission tomography); Cam-CAN (Cambridge Centre for Ageing and 
Neuroscience); AD/MCI+ (Alzheimer’s disease and MCI PiB positive mild cognitive 
impairment patients); MLR (multiple linear regression analyses); NIMROD (Neuroimaging 
of Inflammation in MemoRy and Other Disorders study) 
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6.3.4. Statistical analyses 
I adopted a two-level procedure, where at the first-level I sought to identify 
functional connectivity differences associated with differences in 
[11C]PK11195 (PK) binding. In a second-level analysis we tested whether 
individual variability in PK-relevant functional connectivity (from first-level 
analysis) is specifically associated with variability in cognitive decline in the 
AD/MCI+ group.  
 
For the first-level analysis, we used multiple linear regression (MLR) with 
well-conditioned shrinkage regularization to identify correlated structured 
sources of variance between functional connectivity and neuroinflammation 
measures. In particular, this analysis describes the linear relationship 
between functional connectivity and SBM-PK maps on a between-subject 
level, in terms of structure coefficients, by providing subject scores (i.e. a 
latent variable) of the functional connectivity measures that are optimised 
to be highly correlated with the between-subject variability in the 
expression of the PK maps. Namely, connectivity strength between pairs of 
network nodes for each individual defined the independent variables, and 
PKIC subject-specific loading values for group differentiating components 
were employed as dependent variable. Covariates of no interest included 
age, years of education, gender, and head motion. This first-level MLR was 
integrated with a 5-Fold Cross–Validation.  
 
To further minimize the non-negligible variance of traditional k-Fold cross-
validation procedure, we repeated each k-Fold 1,000 times with random 
partitioning of the folds to produce an R-value distribution, for which we 
report the median values. Next, we tested the hypothesis that the effect of 
neuroinflammation on functional connectivity is related to cognitive deficits, 
in AD patients relative to controls. To this end, we performed a second-level 





Independent variables included subjects’ brain scores from first level MLR, 
group information, and their interaction term (brain scores x group). The 
dependent variable was subjects’ loading values of the first PCA across the 
three cognitive tests. Covariates of no interest included age, gender, head 
movement, and global GM volume.  
 
6.4. Results  
6.4.1. Source-Based ‘Inflammetry’ (SBI) 
The optimal number of components (n=5) was detected with minimum-
distance length (MDL) criteria. One component showed significant 
differences between the AD and control groups in terms of their loading 
values (PKIC3, t-value = -2.1, p-value = 0.046) (Figure 19, right panel).  
 
The spatial extent of this PKIC3 included voxels with high values in cortical 
and subcortical regions, including the inferior temporal cortex and 
hippocampus, indicating that individuals with higher loading values, in this 
case the AD/MCI+ group, had high [11C]PK11195 binding in these regions 
(Figure 19, left panel).   
 
The other components did not differentiate patients from controls (Figure 
20, first row). Interestingly, the PKIC3 component, which differed between 
AD patients and controls, was also the only SBI component that negatively 
correlated with total grey-matter values in AD patients but not controls 
(Figure 20, 2nd and 3rd row). 
 
In other words, the AD patients expressing higher [11C]PK11195 binding in 
the inferior temporal cortex and hippocampus showed also higher levels of 
cortical atrophy (Figure 20, 2nd and 3rd row). This implies that the PKIC3 
component reflects AD-specific patterns of neuroinflammation and 
neurodegeneration. These patterns were next tested in terms of their 
relevance for changes in large-scale network function and their interactive 




Figure 19: Source-based-‘inflammetry’ (SBI) from [11C]PK11195 PET imaging. 
Source-Based Inflammetry for the component differentially expressed between groups: 
(left) independent component (IC) spatial map reflecting increase in [11C]PK11195 binding 
values in cortical and subcortical areas including inferior temporal cortex and hippocampus, 
regionally specific increase over and above global PK differences between groups (regions 
in red), (right) bar plot of subject loading values for AD/MCI+ and control group (each 
circle represents an individual) indicating higher loading values for AD/MCI+ than control 
group as informed by two-sample unpaired permutation test. AD/MCI+ (Alzheimer’s 




Figure 20: Source-based-‘inflammetry’ (SBI) derived indpendent components . 
The Source-Based Inflammetry (SBI) identified five independent components (IC) which 
reflected [11C]PK11195 (PK) binding values in cortical and subcortical areas. The PKIC3 
component was the only component which differed between AD/MCI+ patients and controls 
(first row, third column). The PKIC3 component was also the only SBI component that 
negatively correlated with grey-matter volumes across the whole-brain in all individuals as 
well as in AD patients alone (but not controls) (second, third, and fourth rows). In other 
words, the AD patients expressing higher [11C]PK11195 binding PKIC3 component 
(reflecting higher binding in the inferior temporal cortex and hippocampus as shown in 
Figure 2) also displayed higher levels of brain-wide atrophy.  
  
 113 
6.4.2. Functional connectivity 
There was a strong positive functional connectivity between all nodes within 
the four networks previously identified by spatially matching to pre-existing 
templates (Figure 21, left panel). In terms of group differences, the 
functional connectivity within the DMN and between the DMN and 
hippocampus was weaker in patients with AD/MCI+ relative to controls 
(Figure 21, right panel). 
 
 
Figure 21: Mean effects of functional connectivity data from rsfMRI. 
Mean effects (left) and group difference effects (AD/MCI+>Controls, right) between default 
mode network (DMN) and subcortical regions using univariate approach. CN- cognitive 
network, SC, sub-cortical network. ACC – anterior cingulate cortex; PCC – posterior 
cingulate cortex; IPL – intraparietal lobule; FPN – fronto-parietal network; Put – Putamen; 
Hipp – Hippocampus, AG – angular gyrus; SFG – superior frontal gyrus; R, right; L, left. 
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6.4.3. Functional connectivity and neuroinflammation 
The first-level multiple linear regression (MLR) model assessing the 
relationship between PKIC3 maps and rs-fMRI connectivity data was 
significant (r=0.52, p<0.001).  
 
The standard coefficients indicated a positive association between the PKIC3 
loading values and variability in functional connectivity (Figure 22, left 
panel). In other words, individuals with higher [11C]PK11195 binding 
values in the inferior temporal cortex and medial temporal lobe regions (as 
reflect by higher PKIC3 values) showed: 1) increased connectivity between 
the DMN and the hippocampus and other subcortical regions (putamen), 
and 2) weaker connectivity for nodes within DMN.  
 
6.4.4. Linking neuroinflammation and connectivity to cognitive 
deficit  
The first cognitive component explained the 80% of the variance across 
cognitive tests (coefficients: .61, .61 and .52 for ACE-R, MMSE, and RAVLT, 
respectively).  
 
To investigate whether the effects of neuroinflammation on functional 
connectivity measures were specific to the AD/MCI+ group, especially in 
relation to cognitive deficits, we tested whether the interaction between 
group and brain scores from first level MLR was associated with COGPC1 
using second-level MLR (see methods).  
 
The interaction term was significant (t=-3.-4, p=0.004). A post-hoc test 
within each group separately indicated opposite association between COGPC1 
and functional connectivity/PK indices (i.e., the residuals) in the AD/MCI+ 
group (r= -0.51, p=0.005) and controls (r=0.46, p=0.096) (Figure 22, 




The negative association in the AD/MCI+ group indicated that patients who 
expressed more strongly the pattern of functional connectivity associated 
with higher [11C]PK11195 binding in cortical (i.e., inferior temporal cortex) 
and subcortical (i.e., hippocampus) regions performed worse on a summary 




Figure 22: Microglia activation, functional connectivity, and cognition in AD. 
(Left) First-level multiple linear regression (MLR) indicating that functional connectivity 
differences (deviating from groups effects in Figure 3) are associated positively with 
[11C]PK11195-related independent component measures (PKIC3).  
(Right) Second level MLR testing the association between PKIC3 pattern of functional 
connectivity and cognitive performance for AD/MCI+ (orange) and control (green) groups. 
ACC – anterior cingulate cortex; PCC – posterior cingulate cortex; IPL – intraparietal lobule; 
FPN – fronto-parietal network; SC– subcortical, DMN – default mode network, DMNd – 
dorsal DMN, Put– Putamen; Hipp – Hippocampus, AG – angular gyrus; SFG – superior 




This study shows that that stronger microglial activation in AD is associated 
with the disruption of large-scale functional connectivity underlying 
cognitive performance. Specifically, the degree to which a patient expressed 
the pattern of abnormal connectivity associated with neuroinflammation 
correlated with the amount of cognitive deficit, across the spectrum of 
patients with AD and MCI+. This is consistent with the hypothesis that 
microglia activation relates to brain-wide connectivity in AD and mediates 
clinically relevant cognitive deficit. Proof of this direction of causality in the 
associations will require anti-inflammatory interventions in AD/MCI+, but 
we suggest that the novel SBI method would be a suitable tool for 
experimental medicine studies.  
 
There are different mechanisms by which microglia activation might alter 
neuronal firing as well as network function and large-scale connectivity 
patterns. For instance, microglia are important contributors in the process 
of synaptic pruning and in monitoring synaptic activity (Hong et al. 2016; 
Hong & Stevens 2016). These functions are mediated by microglia’s highly 
mobile and ramified branches that can reach and surround the synaptic 
terminals to promote phagocytosis and synaptic demise (Hong et al. 2016; 
Hong & Stevens 2016). Microglia-induced complement activation might also 
contribute to synaptic dysfunction and loss, especially in the context of 
amyloid deposition and neuritic plaque formation (Hong et al. 2016; Hong 
& Stevens 2016).  
 
The anatomical distribution of microglia activation in AD and its distinct 
effects on network function within the default mode network (DMN) and 
between the DMN and medial temporal lobe supports the notion that 
neuroinflammation may be an early event in the etio-pathogenesis of AD. 
The DMN and medial temporal lobe are key circuits in the episodic memory 
system and have been consistently implicated in the pathophysiology of 
early stages of AD.  
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In terms of limitations, I recognize that the multi-variate method of 
statistical associations used here does not in itself demonstrate causality 
between microglia activation, network dysfunction, and cognition. Recent 
longitudinal studies in AD have shown that changes in [11C]PK11195 binding 
may be linked with disease progression (Fan et al. 2015a; Kreisl et al. 
2016), although this does still not prove causality for which pre-clinical 
experiments are necessary. Further research is also needed to assess 
whether longitudinal changes in [11C]PK11195 binding relate to changes in 
network function.  
 
Even more importantly, it remains to be ascertained whether the putative 
effects of anti-inflammatory therapies have an impact in reducing the 
deleterious effect of neuroinflammation on brain functioning and 
consequently cognitive performance.  
 
There are other limitations to consider. These include the necessity to 
replicate our findings in independent and larger clinical cohorts, although 
the difficulty in terms of costs and recruitment should not be dismissed.  
 
To mitigate the notoriously challenging issues related to head motion 
artefacts in fMRI studies, I have adopted two main strategies that included:  
 
1) a robust pre-processing pipeline using Multi-Echo Independent 
Components Analysis (ME-ICA), to classify blood oxygenation dependant 
(BOLD) and non-BOLD signals;  
 
2) the inclusion, as covariates of no interest, of movement-related 
parameters in the second-level statistical analyses.  
 
At the clinical and phenotypic level, it remains to be determined whether 
the deleterious impact of microglia activation on network function can be 
revealed in pre-symptomatic carriers of genetic mutations liked to familiar 
forms of AD. Answering this question has important consequences for 
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understanding the timing of neuroinflammation in AD and its relationship to 
neuronal dysfunction, cell loss, and cognitive decline.  
 
In conclusion, this study suggests that microglia activation plays an 
important role in mediating functionally relevant changes in brain 
connectivity in AD. Heterogeneity in cognitive performance is associated 
with variability in neuroinflammation-related brain dysfunction.  
 
Alongside the data presented in chapter 4, these findings emphasize the 
importance of using multi-modal neuroimaging to study how different 
aspects of the molecular pathology in AD affect network function and 
cognitive impairment.   
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Chapter 7| General Discussion 
 
7.1. Summary 
The main aim of my thesis was to improve our understanding of in vivo tau 
pathology and neuroinflammation in relation to network dysfunction and 
cognitive deficit in AD. To this end, I used multi-modal imaging that 
combined specific PET ligands and state-of-art rsfMRI graph and 
multivariate analyses.  
 
I studied a cohort of patients with clinically probable AD and MCI with PET 
biomarker evidence of amyloid pathology. This phenotypically variable 
group of patients was also defined in terms of individual differences in 
neuropsychological profiles and was compared to groups of age-, sex-, and 
education-matched healthy controls. The cognitive profile in patients with 
AD/MCI+ was fully consistent with previous findings in larger populations.  
 
However, I acknowledge that the phenotypic spectrum and variability in 
clinical severity in the patients’ group included in my thesis was limited by 
the inclusion of participants with early stages of the disease. This, alongside 
the small sample sizes in each of the clinical groups, did not offer sufficient 
power to decompose the effects of Braak’s staging on the main imaging 
findings.  
 
Furthermore, my thesis did not examine the relationship between tau 
pathology and neuroinflammation in AD, neither how the interplay of these 
molecular pathologies affected brain function and cognition. These are 
certainly interesting and important aspects to study in future research, but 
they were beyond the more focused scope of my PhD (although see 





My thesis tested two main hypotheses:  
 
1) that the extent and localization of in vivo tau pathology and 
neuroinflammation in patients with AD/MCI+ mirrored the disease-specific 
patterns of degeneration, especially in brain areas that are affected early in 
the disease (e.g., medial temporal lobe regions);  
 
2) that in vivo tau pathology and neuroinflammation mediated network 
dysfunction and severity of cognitive deficit. 
 
Overall, my studies support the idea that tau burden and microglia 
activation are key pathophysiological mechanisms underlying Alzheimer’s 
disease and its associated clinical heterogeneity. Despite previous 
progresses in understanding the molecular pathologies leading to AD, the 
clinical and intermediate phenotypic correlates (i.e., network function) of 
tau pathology and neuroinflammation have remained unclear and poorly 
studied.  
 
The main contribution of my findings is that they provide a ‘bridge’ between 
basic and clinical research and facilitate future developments of translation 
work that will improve the clinical management and disease-modifying 
treatment of AD.  
 
The findings of my studies have also other implications.  
 
The data presented in chapters 3 and 4 provide evidence , in humans, that 
the tau burden in AD shows specific neuroanatomical patterns and is 
associated with the degree of functional connectivity rather than depending 
on the proximity of brain regions (Goedert 2015). This trans-neuronal 
hypothesis of tau abnormal diffusion was initially proposed on the basis of 
rodent studies which showed that the injection of brain extract from tau 
transgenic mice into mice expressing wild-type human tau causes this wild-
type tau to develop abnormal tau filaments that spread across the brain 
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(Clavaguera et al. 2009). Similarly, pathological tau extract from brains of 
AD patients produce AD-like disease in wild-type mice, in whom 
pathological human tau becomes self-propagating (Clavaguera et al. 2013). 
This spreading of abnormal tau is mediated by the strength of synaptic 
connectivity rather than by the spatial proximity of the brain regions or 
neurons (Liu et al. 2012; Iba et al. 2013; Ahmed et al. 2014).  
 
In my studies, we were able to measure in vivo tau burden, via [18F]AV-
1451 PET, and directly link this measure with indices of resting-state 
functional connectivity in living patients with AD. Our data showed that the 
brain areas that were more strongly connected accrued more tau pathology, 
consistently with the hypothesis of trans-neuronal propagation of the tau 
protein. We also found that the presence of tau pathology itself was not 
linked with higher regional connectivity but in contrast increased tau 
accumulation was associated with weaker functional connectivity in AD. The 
fact that in healthy people the [18F]AV-1451 binding at each node explained 
more regional variance in connectivity changes rather than connectivity of 
that node also suggest that tau is not a secondary marker of 
neurodegeneration in vulnerable hubs.  
 
The data presented in chapters 5 and 6 provide support to the notion that 
microglia activation and neuroinflammation are not merely epiphenomena 
of neurodegeneration, but are important etio-pathogenetic mediators of AD 
symptomatology (Villegas-Llerena et al. 2016). Recent genome-wide 
association studies have challenged the previous assumption that 
neuroinflammation is a by-product of neurodegeneration and have in 
contrast sustained a primary role of microglia activation in the aetiology of 
AD (Guerreiro et al. 2013a; Jonsson et al. 2013b). For instance, mutations 
in TREM2, an immune cells receptor expressed on microglia, have been 
shown to represent an important risk factor for sporadic and late-onset 
cases of AD (Guerreiro et al. 2013a; Jonsson et al. 2013b). Together with 
the results presented in chapter 5 and 6, this lends further support to the 
proposal that targeting neuroinflammation might reduce the progression of 
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AD. In more general terms, my findings reinforce the value of using 
biomarkers based on PET imaging and network function as indices of 
relevant intermediate phenotypes, between pathology and clinic. My data 
also support the idea that functional dys-connectivity can be considered an 
important intermediate phenotypic expression of tau and inflammatory 
pathology in AD. This is relevant to new strategies for stratifying patients 
and quantifying outcome measures in future clinical trials that aim to target 
abnormal tau accumulation and neuroinflammation.  
 
This is a key issue, especially when considering the striking contrast 
between the positive findings from basic research on the role of tau 
pathology and microglia activation in AD (Heppner et al. 2015), and the 
negative findings from human studies which have provided so far little 
support for immune-therapeutic strategies in AD (Adapt Research Group et 
al. 2007, 2008), despite initial epidemiological evidence (Breitner & Zandi 
2001; in t’ Veld et al. 2001). 
 
These apparently conflicting results may be reconciled by investigating how 
tau propagation and neuroinflammation influence the intermediate 
phenotypes of large-scale network functional connectivity in AD. Clinical 
trials may fail to demonstrate a role for immune-therapeutic strategies 
targeting tau pathology and microglia activation in AD due to elevated 
heterogeneity in patients’ data. The data presented in chapter 6 confirm the 
marked heterogeneity in the relationship between resting-state functional 
connectivity and neuroinflammation in AD patients. This variance was also 
significantly related to inter-individual differences in cognitive performance.  
 
Overall, my studies are in keeping with the literature emphasizing the 
molecular and clinical complexity of AD and the necessity to target different 
aspects of this disorder to provide more realistic and efficient treatments as 
well as to empower and de-risk clinical trials. The observation of the high 
heterogeneity in terms of tau burden, microglia activation, and network 
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dysfunction across the spectrum of AD syndromes has important 
implications for the planning of future studies and clinical trials.  
 
For example, clinical and non-clinical research attempting to assess the 
molecular and phenotypic complexity of AD may benefit from stratifying 
patients based on the presence and severity of tau burden and 
neuroinflammation, rather than on diagnostic categories alone. The choice 
of the most appropriate and sensitive outcome measures is critical for more 
efficient clinical trials; hence, in vivo and pathological-specific assessment 
tools are desperately warranted in AD research. 
 
Clarifying the link between tau pathology, microglia activation, and 
cognitive decline in AD is thus critical for developing novel therapies. 
Together or even in isolation, tau burden and neuroinflammation may 
represent important biomarkers of AD which might help identifying and 
stratifying patients with the most severe or rapidly progressive forms of the 
disease.  
 
For example, if tau propagation and/or neuroinflammation occur early in 
AD, they can represent markers of initial disease changes, or “pre-
diagnostic” tools to track the risk of cognitive deterioration and 
development of dementia. However, it remains to be clarified when tau 
pathology and neuroinflammation become fully apparent and which is their 
causal relationship. Studies on pre-symptomatic carriers of genetic 
mutations known to cause AD may be able to show brain changes in terms 
of tau burden and neuroinflammation 5-10 years prior to the onset of full-
blown dementia (Rohrer et al. 2015).  
 
These pre-symptomatic individuals may exhibit molecular and neuronal 
changes that occur years before the functional decline that triggers a clinical 
diagnosis of AD. Whether increased tau burden and/or neuroinflammation 
is evident in these genetically predisposed people warrants further 
investigation in large cohorts of individuals and using the appropriate 
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assessment tools which include PET and functional imaging; in essence the 
multi-imaging approach that I have employed in my thesis.  
 
Another open issue is the impact of tau pathology and neuroinflammation 
on ‘cognitive reserve’. This theoretical concept suggests that specific 
factors, such as sex, education, pre-morbid intelligence, and even 
bilingualism, can influence the subject-specific capacity of the brain to 
sustain neurodegenerative insult which in turn can modulate the disease 
onset and clinical manifestation of AD (Garibotto et al. 2012; Perani & 
Abutalebi 2015; Malpetti et al. 2017; Perani et al. 2017; Borsa et al. 2018).  
 
The individuals with greater cognitive reserve are therefore hypothesized to 
have increased brain networks’ flexibility, which increases their ability to 
sustain greater levels of pathology before presenting clinical symptoms. My 
hypothesis is that individuals with higher cognitive reserve may be able to 
tolerate higher levels of tau pathology and neuroinflammation.  
 
Future studies aiming to disentangle the complexity of tau pathology and 
neuroinflammation in AD, as well as their intermediate brain phenotypes at 
the structural and functional connectivity level should be developed to 
classify patients based on the presence and severity of tau pathology and 
microglia activation. Furthermore, the future choice of assessment and 
therapeutic tools should be tailored on single patients’ needs which might 
depend on individual levels of tau burden, neuroinflammation, and network 
function.  
 
Better translational tools are required for this. The in vivo assessment of 
tau pathology and microglia activation might provide good face validity and 
may offer a better platform for translation between pre-clinical and human 
studies. Carefully designed clinical trials targeting the relevant patients and 
using the appropriate outcome measures will clarify whether effective 
intervention directed at tau propagation and neuroinflammation, 
simultaneously or independently, is disease modifying.  
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7.2. Limitations 
7.2.1. Demographic and clinical limitations 
I only included patients with the typical clinical forms of AD and MCI (i.e., 
amnestic type of AD and MCI+).  Although the inclusion of cognitively milder 
forms of AD (i.e., MCI+) extended the variability of the clinical spectrum to 
power the analyses looking at individual differences in terms of in vivo brain 
pathologies and network function, my inclusion and exclusion criteria have 
inevitably limited the relevance of my findings to the broader phenotypic 
spectrum of AD.  
 
The clinical phenotype of AD is wide and includes typical and atypical forms 
of AD such as the posterior cortical atrophy (PCA), the corticobasal 
syndrome (CBS), and the logopenic variant of primary progressive aphasia 
(lvPPA). The fact that I did not include in my thesis these distinct, although 
clinically and pathologically overlapping groups, reduced the generalizability 
of my findings in terms of answering important mechanistic questions about 
the relationship between tau pathology, neuroinflammation, brain function, 
and clinical severity in the broader spectrum of AD disorders. 
 
A recruitment bias may occur towards or away from those patients with 
early disease stages. This is a common issue in complex studies like 
NIMROD in which the intense clinical, behavioural, and multi-modal imaging 
assessment typically biases the recruitment to those individuals who are 
sufficiently ‘robust’ to complete a challenging study protocol. In other 
words, patients with severe forms of AD that significantly limited patients’ 
functioning in daily activities were less likely to be recruited in our studies. 
The presence of a reliable carer was also another aspect that may have 
biased the recruitment to those patients with stronger family support. On 
the other hand, people with early stage symptomatic disease may not be 
diagnosed or engaged in research until several years have passed.  
 
Overall, these demographic and enrolment criteria, as well as the fact that 
some of the patients were recruited from highly specialized tertiary clinics 
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for memory disorders in Cambridge, can have led to the inclusion of a less 
representative sample of patients with AD than those present in the general 
population. This is also in part due to the lack of the inclusion of those 
patients with co-morbidities, mixed dementia, or severe disease stages. 
 
7.2.2. Technical limitations 
Two different PET scanners were used during the NIMROD study. This 
depended on hardware changes and installations of new PET-MR scanner at 
the Wolfson Brain Imaging Centre (WBIC), following the study start with 
PET-CT. Fortunately, this technological issue was only present in n=6 
participants and the number of patients and controls were equally 
distributed across the two scanners. Nevertheless, the use of two different 
scanners inevitably caused an uncontrolled source of noise and variability 
in the data. We also considered to include the scanner site as a covariate of 
no interest in the statistical models, but successively we decided against 
this as the inclusion of another variable could have further reduced the 
degrees of freedom and consequently the statistical power.  
 
There is also variability in the dose of the radioligands administered to each 
participant. We tried to minimize this problem by pre-determining a 
minimum dose that was needed in order to proceed to the scanning of the 
participants. This implies that any dose difference across participants was 
over and above a minimum threshold that was set up to provide a sufficient 
signal to noise ratio for robust modelling and pre-processing of the PET 
data.  
 
A final, but important, technical limitation of the AV1451 ligand regards its 
off-target binding. Despite its strong in vivo and post mortem binding to 
AD-related tau pathology, there is also evidence that AV1451 can bind to 
other, non tau-pathologies such as for example TDP43 pathology (Bevan-
Jones et al. 2017a). Other studies have also suggested alternative ‘off-
target’ binding sites including neuromelanin (Marquié et al. 2015) and 
monoamine oxidase B (Harada et al. 2017; Jang et al. 2018). Consequently, 
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this off-target binding has spread concerns and caution regarding the use 
of AV1451 as a reliable marker of tau pathology.  
 
However, it should be noted that the ‘off-target’ sites of the AV1451 binding 
are likely to vary according to the brain region and pathological effects 
examined. For instance, the neuromelanin ‘off-target’ binding can only be 
expected in the substantia nigra and locus coeruleus, two brainstem regions 
which are rich of neuromelanin, a pigmented polymer that accumulates as 
a consequence of the presence of cytosol catecholamines like dopamine and 
noradrenaline. This is not the case in the basal ganglia nor in cortical regions 
which do not contain or accumulate neuromelanin (Hansen et al. 2016). In 
other words, the neuromelanin hypothesis of the ‘off-target’ binding of 
AV1451 cannot explain in itself the high unspecific binding that we and 
others observed in vivo in the basal ganglia (see Figure 9).  
Our post mortem data published in Passamonti et al., 2017 (Brain), also 
clearly showed that off-target binding to neuromelanin cannot be the cause 
for [18F]AV1451 uptake in the basal ganglia or the cortex. In particular, we 
found significant in vivo [18F]AV1451 uptake in the basal ganglia (in all 
groups including healthy controls) (Figure 9 and 10) in the absence of 
post mortem neuromelanin-containing cells in these sub-cortical regions 
(Passamonti et al. 2017b). This shows that neuromelanin is not the main 
target of off-target binding for [18F]AV1451, at least in the basal ganglia 
and the cortex which do not display accumulation or deposit of 
neuromelanin (Passamonti et al. 2017b).   
 
In the basal ganglia, however, the MAO-A enzyme is significantly expressed 
and this has been offered as an alternative explanation for the ‘off-target’ 
binding of tau PET compounds like THK5351 (Ng et al. 2017). Other work 
has also proposed the MAO-A enzyme as another off-target binding site of 
AV1451 (Vermeiren et al. 2018), although a definitive displacement study 
has not been conducted yet.  
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Another important aspect regards the fact that the MAO enzyme (albeit of 
type B not A) has been found to be expressed in activated microglia, which 
raises the critical issue of whether the AV1451 binding relates not only to 
tau pathology in AD, but also to activated microglia, the typical binding site 
of the TSPO PK11195 ligand. However, this hypothesis is not confirmed by 
our recent data in a pre-symptomatic carrier of a MAPT genetic mutation 
which showed that PK11195 binding is possible in the absence of AV1451 
uptake (Bevan-Jones et al. 2019). Nevertheless, we could not be sure of 
presence of tau pathology in this single case as post mortem data were not 
available so further studies need to be conducted to reveal the exact nature 
of the ‘off-target’ binding of the AV1451 tracer. Additional studies are also 
necessary to study the relationship between AV1451 binding in non-AD and 
non tau-related degenerative diseases such as TDP43 disorders (e.g., 
semantic dementia) (Bevan-Jones et al. 2017b, 2018).  
 
7.2.3. Methodological limitations 
My studies have also limitations in terms of the analytical methods 
employed to analyse the PET and rsfMRI data. 
 
7.2.3.1 PET methodological limitations 
First, I acknowledge the arbitrary selection of the reference region that is 
used to modelling the PET tissue specific binding. This arises for the [18F]-
AV1451 imaging pre-processing procedures for which arterial sampling 
reference data from the literature were not available at the time of the data 
acquisition (due to the novelty of this PET compound). It was also beyond 
the scope of the NIMROD study to acquire normative data for unspecific 
binding of the AV1451 tracer which would have required a separate ethical 
approval and funding structure. 
 
As reference region for the PET AV1451 tracer unspecific binding, we 
decided to use the white-matter in the superior cerebellum as this area was 
unlikely to be affected by AD pathology, especially at relatively early stages 
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of the disease. This idea was corroborated by our post mortem findings 
published in the supplementary material of Passamonti et al, 2017 (Brain) 
in which we showed the absence of tau pathology in the white-matter of 
the superior cerebellum in AD. 
 
For the PK11195 PET imaging, the reference region was determined with a 
fully automated and data driven approach that employed supervised cluster 
analysis and avoided the use of arbitrarily chosen brain reference areas. 
This was possible because arterial reference data for unspecific binding were 
available from a large literature of previous studies using the PK11195 
compound.  
 
Second, our regional PET analyses used partial volume correction for 
cerebrospinal fluid (CSF), which controlled for differences in CSF signal 
contamination within each region and across the different diagnostic groups 
(i.e., AD/MCI+ and healthy control groups). This approach is important to 
reduce the potential influence of brain volume loss (i.e., atrophy) that is 
typically observed in AD, although it can artificially introduce errors due to 
the imperfect co-registration of PET and MRI data. I note, however, that 
this potential issue was significantly mitigated by the fact that the main 
results were replicated when using uncorrected PET data (see Results 
section of Chapter 3 and 5). 
 
7.2.3.2 rsfMRI methodological limitations 
Two main limitations of the rsfMRI analytical pipelines are discussed: 
 
First, I acknowledge that associative methods do not in themselves 
demonstrate causality between tau pathology neuroinflammation, network 
dysfunction, and cognition. To address the causal chain leading to cognitive 
dysfunctions in AD, from their molecular and brain antecedents to the 
clinical symptoms, longitudinal and interventional studies are needed 
alongside mediation analyses. This clearly spans not only rsfMRI data alone, 
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but any type of data included in my thesis such as PET as well as clinical 
and behavioural data. 
 
Second, the confounding effect of head motion on functional imaging has 
been fully recognized as both a challenging and critical factor for 
interpretation of functional imaging studies, especially in clinical populations 
which can present with an increased rate of head movement during fMRI 
scanning. To minimize this potentially important confound, we adopted two 
procedures.  
 
1) We used independent component analyses that had been previously 
validated to neatly separate the changes in the fMRI signal that are related 
to the BOLD and non-BOLD components (Kundu et al. 2012b, 2013a). This 
procedure has been shown to be particularly robust in de-noising fMRI data 
from several sources of noise including head movement (Kundu et al. 
2012b, 2013a).  
 
2) we included movement-related parameters as covariates of no interest 
in second-level analyses, as well as motion and physiological signals in first-
level analyses. This co-variance approach was employed to mitigate the 
residual effects of movements on brain functional components estimated in 
the statistical models used to assess network connectivity. 
 
7.3. Final discussion and future directions  
Despite the above described limitations in the ‘off-target’ binding of the 
[18F]AV1451, the confidence regarding this PET compound as a biomarker 
of tau pathology in AD remain high. The new longitudinal findings showing 
that [18F]AV1451 PET is able to track the disease progression and clinical 
severity, alongside the complexity of the phenotypic spectrum in AD is 
encouraging and supports the view that this tracer is a reliable and valid 
marker for assessing and tracking in vivo tau pathology in AD (Harrison et 
al. 2019; Pontecorvo et al. 2019).  
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The disease specific pattern of binding of the [18F]AV1451 PET ligand also 
remains a useful intermediate phenotype of tau pathology in AD to 
characterize the tau-related network dys-connectivity that is typically 
observed in AD (Cope et al., 2018, Brain). These properties can have further 
applications in terms of development of more sensitive and specific 
biomarkers for the diagnosis of AD and for additional studies assessing the 
pathophysiological mechanisms that relate to cognitive dysfunction and 
disease severity in AD. Future longitudinal  studies will be also determinant 
in assessing the effect of the newly developed anti-tau disease-modifying 
therapies on intermediate phenotypes of brain pathology and function, 
before the clinical endpoints (Ossenkoppele et al. 2018). 
 
In terms of the potential utility of [18F]AV1451 PET to discriminate between 
AD- and non-AD tauopathies or other neurodegenerative disorders this has 
not been fully evaluated yet, although initial findings from our group are 
promising (Passamonti et al., 2017, Brain). 
Another aspect that is central in my thesis is the key etio-pathogenetic role 
of neuroinflammation in AD, and especially its contribution in mediating 
anomalies in functional connectivity, and cognitive impairment. This is in 
keeping with the mechanistic evidence showing increased microglial 
activation and neuroinflammation as the disease progresses. Nevertheless, 
despite the epidemiological (McGeer et al. 1996; in ’t Veld et al. 2001), 
genetic (Malik et al. 2015; Zhang et al. 2015) and PET (Edison et al. 2008b; 
Esposito et al. 2008; Carter et al. 2012) evidence providing strong support 
for neuroinflammation in AD, its causal role in the pathogenesis of AD 
remains to be confirmed. 
 
Several, and not necessarily mutually exclusive, possibilities exist to explain 
the involvement of microglia activation and neuroinflammation in AD: (i) 
these molecular processes can be independent causes of AD, over and 
above tau and amyloid pathologies; (ii) they may be secondary effects of 
tau protein aggregation or amyloid deposition or even secondary event to 
the generation of protein oligomers, before pathological protein aggregation 
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and diffusion; (iii) they might be reactive consequences of neuronal death 
and synaptic loss (which is an unlikely hypothesis but still does not to be 
completely ruled out). Only interventional and longitudinal studies using 
causal statistical modelling (e.g., mediation analyses, Bayesian inference) 
can resolve these critical issues and answer these open questions.  
 
Past epidemiological evidence using retrospective data have suggested a 
partially protective effect of anti-inflammatories in the progression or even 
development of AD. However, these studies were correlational in nature 
and did not employ randomised placebo-controlled interventional designs 
that can overcome the classic shortcomings of some epidemiological 
research.  
 
Nevertheless, our finding of an association between microglia activation and 
cognitive impairment, as well as between neuroinflammation, network 
dysfunction and individual differences in cognitive deficit represent a 
promising set of data that further motivate studying and assessment of the 
role of neuroinflammation in AD.  
 
I also would like to reiterate that my thesis did not examine the relationship 
between tau pathology and neuroinflammation in AD, neither how the 
interplay of these molecular pathologies affected brain function and 
cognition.  
 
It is however worth noting that my colleagues in the NIMROD team have 
already began to investigate the intriguing association between in vivo 
neuroinflammation and tau pathology in AD. For example, we have initial 
(i.e., submitted but not published yet) data showing that tau pathology (as 
assessed via AV PET) positively relate to microglia activation (as assessed 
via PK PET) in AD.  
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These preliminary findings are shown in Figure 23, in which strong positive 
associations between [18F]AV1451 and [11C]PK11195 binding can be 
observed across several brain ROIs in AD. 
 
 
Figure 23: Relation between tau burden and neuroinflammation in AD. 
There is a positive relationship between [18F]AV-1451 and [11C]PK-11195 PET binding 
across different brain regions (coded with different colours) in AD. 
  
 134 
Another key aspect that forthcoming studies need to tackle regards the use 
of larger sample sizes to improve the generalizability of the findings to the 
broad phenotypic spectrum of AD and to better assess the high clinical 
variability in the different cognitive features that characterize AD patients. 
Such studies will have enhanced statistical power to detect significant 
associations between markers of brain pathology, measures of network 
function, and heterogeneity in behavioural and cognitive symptoms. If 
sufficiently large, these studies can also have the power to assess the effect 
of genetic risk factors on brain intermediate phenotypes of pathologies as 
well as on brain structure and function. 
 
Thus far the study  by Ossenkoppele and colleagues has been seminal in 
this direction as it clearly demonstrated that different  types of AD including 
the amnestic-AD, PCA-AD and logopenic variant of AD were robustly 
associated with specific patterns of tau pathology but not amyloid 
deposition (Ossenkoppele et al. 2016c).  
 
I also envisage the obvious necessity to develop second generation tracers 
with increased sensitivity and specificity for AD-related tau pathology and, 
paraphs even more importantly, with the ability to discriminate between 
the 3R and 4R isoforms of tau that will enhance the differential diagnosis 
between AD- and non-AD tauopathies.  Currently, PBB3 seems to show 
promises in that direction, although additional data are needed (Talakad 
Lohith, Idriss Bennacef, Zhizhen Zeng, Marie Holahan, Michel Koole, Koen 
Van Laere, Cyrille Sur, Arie Struyk 2016; Betthauser et al. 2018; Pascoal et 
al. 2018).  
 
The final direction of future research regards the important application of 
tau-PET and microglia-PET to inform etio-pathological models of AD, 
especially via the use of multimodal neuroimaging that can offer 
complementary information about different, but synergistic, mechanisms of 
disease. Two chapters in this thesis (Chapter 4 and Chapter 6) present 
encouraging findings showing that tau-PET and inflammatory-PET can be 
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individually combined with another imaging modality (rsfMRI) to test the 
‘transmission hypothesis’ of tau spreading in humans (in which tau diffusion 
follows specific connectivity patterns rather than proximity rules) and the 
role of neuroinflammatory dependent dysconnectivity in mediating clinical 
severity in AD. Over and above our studies, in the last few years, there has 
been a growing interest in assessing different pathophysiological aspects of 
AD via the complimentary use of different neuroimaging techniques 
(Brundin et al. 2010; Lee et al. 2010; Jucker & Walker 2011).  
 
Although this approach poses some conceptual, technical, and 
methodological challenges that I have discussed throughout this thesis 
(e.g., reduction of data dimensionality), multimodal neuroimaging can play 
an important role in disentangling the complex nature of the pathologies 
underlying AD. This and other neurodegenerative disorders are caused by 
a multifaceted number of factors that are likely to interact at many different 
levels in the brain. Our cross-modal multivariate analyses and findings 
emphasize the value of multi-modal neuroimaging to study how different 
aspects of the molecular pathologies of AD mediate brain function and 
cognition. Improved stratification procedures may facilitate more efficient 
therapeutic trials in AD, based not only on tau pathology, 
neuroinflammation, brain atrophy or functional connectivity, but on their 
compound interplay that leads to individual differences in cognitive 
impairment. 
 
7.4. Conclusion  
My research shows the advantages of multi-modal imaging approaches to 
assess a pathologically and clinically complex neurodegenerative disorder 
such as AD.  
 
The causal interactions between tau burden, neuroinflammation, network 
function in AD remain to be elucidated and linked to cognitive decline before 
new disease-modifying treatments can be developed and implemented in 
the clinical practice. Novel, pathologically-specific, and translational 
 136 
therapies should consider the individual degree of tau burden and/or 
microglia activation in single patients with AD, moving away from including 
patients in clinical trials only on the basis of a clinical diagnosis that does 
not incorporate the ‘added’ informative value of biomarkers probing 
different phenotypic levels.  
 
The heterogeneity across patients with AD pathologies in terms of tau 
burden, microglia activation, and network function should be considered to 
empower and de-risk future clinical trials and to improve outcome measures 
based non only on clinical endpoints but also on brain-derived and 
mechanistically-focussed measures. 
 
The complex nature of the molecular pathways leading to AD suggests the 
need for combinational or ‘cocktail’ disease-modifying therapy, for example, 
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